1
|
Bidan N, Lores S, Vanhecke A, Nicolas V, Domenichini S, López R, de la Fuente M, Mura S. Before in vivo studies: In vitro screening of sphingomyelin nanosystems using a relevant 3D multicellular pancreatic tumor spheroid model. Int J Pharm 2022; 617:121577. [PMID: 35167901 DOI: 10.1016/j.ijpharm.2022.121577] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2021] [Revised: 02/07/2022] [Accepted: 02/09/2022] [Indexed: 12/13/2022]
Abstract
Sphingomyelin nanosystems have already shown to be promising carriers for efficient delivery of anticancer drugs. For further application in the treatment of pancreatic tumor, the investigation on relevant in vitro models able to reproduce its physio-pathological complexity, is mandatory. Accordingly, a 3D heterotype spheroid model of pancreatic tumor has been herein constructed to investigate the potential of bare and polyethylene glycol-modified lipids nanosystems in terms of their ability to penetrate the tumor mass and deliver drugs. Regardless of their surface properties, the lipid nanosystems successfully diffused through the spheroid without inducing toxicity, showing a clear safety profile. Loading of the bare nanosystems with a lipid prodrug of gemcitabine was used to evaluate their therapeutic potential. While the nanosystems were more effective than the free drug on 2D cell monocultures, this advantage, despite their efficient penetration capacity, was lost in the 3D tumor model. The latter, being able to mimic the tumor and its microenvironment, was capable to provide a more realistic information on the cell sensitivity to treatments. These results highlight the importance of using appropriate 3D tumour models as tools for proper in vitro evaluation of nanomedicine efficacy and their timely optimisation, so as to identify the best candidates for later in vivo evaluation.
Collapse
Affiliation(s)
- Nadege Bidan
- Institut Galien Paris-Saclay, UMR 8612, CNRS, Université Paris-Saclay, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, F92296 Châtenay-Malabry cedex, France
| | - Saínza Lores
- Nano-Oncology and Translational Therapeutics Unit, Health Research Institute of Santiago de Compostela (IDIS), SERGAS, 15706 Santiago de Compostela, Spain
| | - Aure Vanhecke
- Institut Galien Paris-Saclay, UMR 8612, CNRS, Université Paris-Saclay, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, F92296 Châtenay-Malabry cedex, France
| | - Valérie Nicolas
- UMS-IPSIT MIPSIT Microscopy facility, Université Paris-Saclay, Inserm, CNRS, Ingénierie et Plateformes au Service de l'Innovation Thérapeutique, 92296, Châtenay-Malabry, France
| | - Severine Domenichini
- UMS-IPSIT MIPSIT Microscopy facility, Université Paris-Saclay, Inserm, CNRS, Ingénierie et Plateformes au Service de l'Innovation Thérapeutique, 92296, Châtenay-Malabry, France
| | - Rafael López
- Translational Medical Oncology group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), SERGAS, 15706 Santiago de Compostela, Spain; Biomedical Research Networking Center on Oncology (CIBERONC), Madrid, 28029, Spain
| | - María de la Fuente
- Nano-Oncology and Translational Therapeutics Unit, Health Research Institute of Santiago de Compostela (IDIS), SERGAS, 15706 Santiago de Compostela, Spain; Biomedical Research Networking Center on Oncology (CIBERONC), Madrid, 28029, Spain.
| | - Simona Mura
- Institut Galien Paris-Saclay, UMR 8612, CNRS, Université Paris-Saclay, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, F92296 Châtenay-Malabry cedex, France.
| |
Collapse
|
2
|
Rodríguez-Nogales C, Desmaële D, Sebastián V, Couvreur P, Blanco-Prieto MJ. Decoration of Squalenoyl-Gemcitabine Nanoparticles with Squalenyl-Hydroxybisphosphonate for the Treatment of Bone Tumors. ChemMedChem 2021; 16:3730-3738. [PMID: 34581019 PMCID: PMC9298071 DOI: 10.1002/cmdc.202100464] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2021] [Revised: 08/30/2021] [Indexed: 12/17/2022]
Abstract
Therapeutic perspectives of bone tumors such as osteosarcoma remain restricted due to the inefficacy of current treatments. We propose here the construction of a novel anticancer squalene‐based nanomedicine with bone affinity and retention capacity. A squalenyl‐hydroxybisphosphonate molecule was synthetized by chemical conjugation of a 1‐hydroxyl‐1,1‐bisphosphonate moiety to the squalene chain. This amphiphilic compound was inserted onto squalenoyl‐gemcitabine nanoparticles using the nanoprecipitation method. The co‐assembly led to nanoconstructs of 75 nm, with different morphology and colloidal properties. The presence of squalenyl‐hydroxybisphosphonate enhanced the nanoparticles binding affinity for hydroxyapatite, a mineral present in the bone. Moreover, the in vitro anticancer activity was preserved when tested in commercial and patient‐treated derived pediatric osteosarcoma cells. Further in vivo studies will shed light on the potential of these nanomedicines for the treatment of bone sarcomas.
Collapse
Affiliation(s)
- Carlos Rodríguez-Nogales
- Chemistry and Pharmaceutical Technology, Faculty of Pharmacy, Universidad de Navarra-IdisNA, Irunlarrea 1, 31008, Pamplona, Spain
| | - Didier Desmaële
- Institut Galien Paris-Sud UMR CNRS 8612, Université Paris-Saclay, Jean Baptiste Clément 5, 92290, Châtenay-Malabry Cedex, France
| | - Víctor Sebastián
- Instituto de Nanociencia y Materiales de Aragón (INMA), CSIC-Universidad de Zaragoza, Mariano Esquillor López, 50008, Zaragoza, Spain
| | - Patrick Couvreur
- Institut Galien Paris-Sud UMR CNRS 8612, Université Paris-Saclay, Jean Baptiste Clément 5, 92290, Châtenay-Malabry Cedex, France
| | - María J Blanco-Prieto
- Chemistry and Pharmaceutical Technology, Faculty of Pharmacy, Universidad de Navarra-IdisNA, Irunlarrea 1, 31008, Pamplona, Spain
| |
Collapse
|
3
|
Rammal H, Al Assaad A, Dosio F, Stella B, Maksimenko A, Mura S, Van Gulick L, Callewaert M, Desmaële D, Couvreur P, Morjani H, Beljebbar A. Investigation of squalene-doxorubicin distribution and interactions within single cancer cell using Raman microspectroscopy. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2021; 35:102404. [PMID: 33932593 DOI: 10.1016/j.nano.2021.102404] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/05/2020] [Revised: 03/10/2021] [Accepted: 04/08/2021] [Indexed: 11/17/2022]
Abstract
Intracellular distribution of doxorubicin (DOX) and its squalenoylated (SQ-DOX) nanoparticles (NPs) form in murine lung carcinoma M109 and human breast carcinoma MDA-MB-231 cells was investigated by Raman microspectroscopy. Pharmacological data showed that DOX induced higher cytotoxic effect than SQ-DOX NPs. Raman data were obtained using single-point measurements and imaging on the whole cell areas. These data showed that after DOX treatment at 1 μM, the spectral features of DOX were not detected in the M109 cell cytoplasm and nucleus. However, the intracellular distribution of SQ-DOX NPs was higher than DOX in the same conditions. In addition, SQ-DOX NPs were localized into both cell cytoplasm and nucleus. After 5 μM treatment, Raman bands of DOX at 1211 and 1241 cm-1 were detected in the nucleus. Moreover, the intensity ratio of these bands decreased, indicating DOX intercalation into DNA. However, after treatment with SQ-DOX NPs, the intensity of these Raman bands increased. Interestingly, with SQ-DOX NPs, the intensity of 1210/1241 cm-1 ratio was higher suggesting a lower fraction of intercalated DOX in DNA and higher amount of non-hydrolyzed SQ-DOX. Raman imaging data confirm this subcellular localization of these drugs in both M109 and MDA-MB-231 cells. These finding brings new insights to the cellular characterization of anticancer drugs at the molecular level, particularly in the field of nanomedicine.
Collapse
Affiliation(s)
- Hassan Rammal
- Translational BioSpectrocopy, BioSpecT, EA 7506, Université de Reims, Faculté de Pharmacie, Reims, France.
| | - Almar Al Assaad
- Translational BioSpectrocopy, BioSpecT, EA 7506, Université de Reims, Faculté de Pharmacie, Reims, France.
| | - Franco Dosio
- Department of Drug Science and Technology, University of Torino, Torino, Italy.
| | - Barbara Stella
- Department of Drug Science and Technology, University of Torino, Torino, Italy.
| | - Andrei Maksimenko
- Institut Galien Paris-Saclay CNRS UMR8612, Université Paris-Saclay, Faculté de Pharmacie, Châtenay-Malabry, France..
| | - Simona Mura
- Institut Galien Paris-Saclay CNRS UMR8612, Université Paris-Saclay, Faculté de Pharmacie, Châtenay-Malabry, France..
| | - Laurence Van Gulick
- Translational BioSpectrocopy, BioSpecT, EA 7506, Université de Reims, Faculté de Pharmacie, Reims, France; Institut de Chimie Moléculaire de Reims, ICMR - UMR 7312, Université de Reims, Faculté de Pharmacie, Reims, France.
| | - Maïté Callewaert
- Institut de Chimie Moléculaire de Reims, ICMR - UMR 7312, Université de Reims, Faculté de Pharmacie, Reims, France.
| | - Didier Desmaële
- Institut Galien Paris-Saclay CNRS UMR8612, Université Paris-Saclay, Faculté de Pharmacie, Châtenay-Malabry, France..
| | - Patrick Couvreur
- Institut Galien Paris-Saclay CNRS UMR8612, Université Paris-Saclay, Faculté de Pharmacie, Châtenay-Malabry, France..
| | - Hamid Morjani
- Translational BioSpectrocopy, BioSpecT, EA 7506, Université de Reims, Faculté de Pharmacie, Reims, France.
| | - Abdelilah Beljebbar
- Translational BioSpectrocopy, BioSpecT, EA 7506, Université de Reims, Faculté de Pharmacie, Reims, France.
| |
Collapse
|
4
|
Coppens E, Desmaële D, Mougin J, Tusseau-Nenez S, Couvreur P, Mura S. Gemcitabine Lipid Prodrugs: The Key Role of the Lipid Moiety on the Self-Assembly into Nanoparticles. Bioconjug Chem 2021; 32:782-793. [PMID: 33797231 DOI: 10.1021/acs.bioconjchem.1c00051] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
A small library of amphiphilic prodrugs has been synthesized by conjugation of gemcitabine (Gem) (a hydrophilic nucleoside analogue) to a series of lipid moieties and investigated for their capacity to spontaneously self-assemble into nanosized objects by simple nanoprecipitation. Four of these conjugates formed stable nanoparticles (NPs), while with the others, immediate aggregation occurred, whatever the tested experimental conditions. Whether such capacity could have been predicted based on the prodrug physicochemical features was a matter of question. Among various parameters, the hydrophilic-lipophilic balance (HLB) value seemed to hold a predictive character. Indeed, we identified a threshold value which well correlated with the tendency (or not) of the synthesized prodrugs to form stable nanoparticles. Such a hypothesis was further confirmed by broadening the analysis to Gem and other nucleoside prodrugs already described in the literature. We also observed that, in the case of Gem prodrugs, the lipid moiety affected not only the colloidal properties but also the in vitro anticancer efficacy of the resulting nanoparticles. Overall, this study provides a useful demonstration of the predictive potential of the HLB value for lipid prodrug NP formulation and highlights the need of their opportune in vitro screening, as optimal drug loading does not always translate in an efficient biological activity.
Collapse
Affiliation(s)
- Eleonore Coppens
- Institut Galien Paris-Saclay, UMR 8612, CNRS, Université Paris-Saclay, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, F-92296 cedex Châtenay-Malabry, France
| | - Didier Desmaële
- Institut Galien Paris-Saclay, UMR 8612, CNRS, Université Paris-Saclay, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, F-92296 cedex Châtenay-Malabry, France
| | - Julie Mougin
- Institut Galien Paris-Saclay, UMR 8612, CNRS, Université Paris-Saclay, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, F-92296 cedex Châtenay-Malabry, France
| | - Sandrine Tusseau-Nenez
- Laboratoire de Physique de la Matière Condensée (PMC), CNRS, Ecole Polytechnique, Institut Polytechnique de Paris, 91120 Palaiseau, France
| | - Patrick Couvreur
- Institut Galien Paris-Saclay, UMR 8612, CNRS, Université Paris-Saclay, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, F-92296 cedex Châtenay-Malabry, France
| | - Simona Mura
- Institut Galien Paris-Saclay, UMR 8612, CNRS, Université Paris-Saclay, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, F-92296 cedex Châtenay-Malabry, France
| |
Collapse
|
5
|
Paroha S, Verma J, Dubey RD, Dewangan RP, Molugulu N, Bapat RA, Sahoo PK, Kesharwani P. Recent advances and prospects in gemcitabine drug delivery systems. Int J Pharm 2021; 592:120043. [DOI: 10.1016/j.ijpharm.2020.120043] [Citation(s) in RCA: 26] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2020] [Revised: 10/17/2020] [Accepted: 10/29/2020] [Indexed: 12/13/2022]
|
6
|
Singh A, Thakur S, Singh H, Singh H, Kaur S, Kaur S, Dudi R, Mondhe DM, Jain SK. Novel Vitamin E TPGS based docetaxel nanovesicle formulation for its safe and effective parenteral delivery: Toxicological, pharmacokinetic and pharmacodynamic evaluation. J Liposome Res 2020; 31:365-380. [PMID: 33050745 DOI: 10.1080/08982104.2020.1835955] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
Docetaxel (DTX) is a highly lipophilic, BCS class IV drug with poor aqueous solubility (12.7 µg/mL). Presently, only injectable formulation is available in the market which uses a large amount of surfactant (Tween 80) and dehydrated alcohol as a solubilizer. High concentrations of Tween 80 in injectable formulations are associated with severe consequences i.e. nephrotoxicity, fluid retention, and hypersensitivity reactions. The present study aims to eliminate Tween 80, thus novel biocompatible surfactant Vitamin E TPGS based nanovesicle formulation of DTX (20 mg/mL) was developed and evaluated for different quality control parameters. Optimized nanovesicular formulation (NV-TPGS-3) showed nanometric size (102.9 ± 2.9 nm), spherical vesicular shape, high drug encapsulation efficiency (95.2 ± 0.5%), sustained-release profile and high dilution integrity with normal saline. In vitro cytotoxicity assay, showed threefold elevation in the IC50 value of the optimized formulation in comparison to the commercial formulation. Further, no mortality and toxicity were observed during 28 days repeated dose sub-acute toxicity studies in Swiss albino mice up to the dose of 138 mg/kg, whereas, commercial formulation showed toxicity at 40 mg/kg. In addition, in vivo anticancer activity on Ehrlich Ascites Carcinoma induced mice showed a significant tumour growth inhibition of 76.3 ± 5.3% with the NV-TPGS-3 treatment when compared to Ehrlich Ascites Carcinoma control. Results demonstrated that the developed Vitamin E TPGS based nanovesicular formulation of DTX could be a better alternative to increase its clinical uses with improved therapeutic efficacy, reduced toxicity and dosing frequency, and sustained drug release behaviour.
Collapse
Affiliation(s)
- Amrinder Singh
- Department of Pharmaceutical sciences, Guru Nanak Dev University, Amritsar, India
| | - Shubham Thakur
- Department of Pharmaceutical sciences, Guru Nanak Dev University, Amritsar, India
| | - Harmanpreet Singh
- Department of Pharmaceutical sciences, Guru Nanak Dev University, Amritsar, India
| | - Harjeet Singh
- Department of Pharmaceutical sciences, Guru Nanak Dev University, Amritsar, India
| | - Sandeep Kaur
- Department of Botanical and Environmental Sciences, Guru Nanak Dev University, Amritsar, India
| | - Satwinderjeet Kaur
- Department of Botanical and Environmental Sciences, Guru Nanak Dev University, Amritsar, India
| | - Rajesh Dudi
- Cancer Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India
| | - Dilip Manikrao Mondhe
- Cancer Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India
| | - Subheet Kumar Jain
- Department of Pharmaceutical sciences, Guru Nanak Dev University, Amritsar, India
| |
Collapse
|
7
|
Rodríguez-Nogales C, Moreno H, Zandueta C, Desmaële D, Lecanda F, Couvreur P, Blanco-Prieto MJ. Combinatorial Nanomedicine Made of Squalenoyl-Gemcitabine and Edelfosine for the Treatment of Osteosarcoma. Cancers (Basel) 2020; 12:cancers12071895. [PMID: 32674353 PMCID: PMC7409287 DOI: 10.3390/cancers12071895] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2020] [Revised: 07/08/2020] [Accepted: 07/11/2020] [Indexed: 01/06/2023] Open
Abstract
Due to chemoresistance and a high propensity to form lung metastasis, survival rates in pediatric osteosarcoma (OS) are poor. With the aim to improve anticancer activity in pediatric OS, a multidrug nanomedicine was designed using the alkyl-lysophospholipid edelfosine (EF) co-assembled with squalenoyl–gemcitabine (SQ–Gem) to form nanoassemblies (NAs) of 50 nm. SQ–Gem/EF NAs modified the total Gem pool exposure in the blood stream in comparison with SQ–Gem NAs, which correlated with a better tolerability and a lower toxicity profile after multiple intravenous administrations in mice. For in vivo preclinical assessment in an orthotopic OS tumor model, P1.15 OS cells were intratibially injected in athymic nude mice. SQ–Gem/EF NAs considerably decreased the primary tumor growth kinetics and reduced the number of lung metastases. Our findings support the candidature of this anticancer nanomedicine as a potential pediatric OS therapy.
Collapse
Affiliation(s)
- Carlos Rodríguez-Nogales
- Chemistry and Pharmaceutical Technology Department, School of Pharmacy and Nutrition, Universidad de Navarra, 31008 Pamplona, Spain;
- IdiSNA, Navarra Institute for Health Research, 31008 Pamplona, Spain; (H.M.); (C.Z.); (F.L.)
| | - Haritz Moreno
- IdiSNA, Navarra Institute for Health Research, 31008 Pamplona, Spain; (H.M.); (C.Z.); (F.L.)
- Solid Tumors Program, Division of Oncology, Centre for Applied Biomedical Research (CIMA), University of Navarra, 31008 Pamplona, Spain
| | - Carolina Zandueta
- IdiSNA, Navarra Institute for Health Research, 31008 Pamplona, Spain; (H.M.); (C.Z.); (F.L.)
- Solid Tumors Program, Division of Oncology, Centre for Applied Biomedical Research (CIMA), University of Navarra, 31008 Pamplona, Spain
| | - Didier Desmaële
- Institut Galien Paris Sud, CNRS UMR 8612, Université Paris-Saclay, 92296 Châtenay-Malabry, France;
| | - Fernando Lecanda
- IdiSNA, Navarra Institute for Health Research, 31008 Pamplona, Spain; (H.M.); (C.Z.); (F.L.)
- Solid Tumors Program, Division of Oncology, Centre for Applied Biomedical Research (CIMA), University of Navarra, 31008 Pamplona, Spain
- Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, 31008 Pamplona, Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain
| | - Patrick Couvreur
- Institut Galien Paris Sud, CNRS UMR 8612, Université Paris-Saclay, 92296 Châtenay-Malabry, France;
- Correspondence: (P.C.); (M.J.B.-P.); Tel.: +33-1-46835396 (P.C.); +34-948425679 (M.J.B.-P.); Fax: 34-948425740 (P.C.); 34-948425740 (M.J.B.-P.)
| | - María J. Blanco-Prieto
- Chemistry and Pharmaceutical Technology Department, School of Pharmacy and Nutrition, Universidad de Navarra, 31008 Pamplona, Spain;
- IdiSNA, Navarra Institute for Health Research, 31008 Pamplona, Spain; (H.M.); (C.Z.); (F.L.)
- Correspondence: (P.C.); (M.J.B.-P.); Tel.: +33-1-46835396 (P.C.); +34-948425679 (M.J.B.-P.); Fax: 34-948425740 (P.C.); 34-948425740 (M.J.B.-P.)
| |
Collapse
|
8
|
Rodríguez-Nogales C, Sebastián V, Irusta S, Desmaële D, Couvreur P, Blanco-Prieto MJ. A unique multidrug nanomedicine made of squalenoyl-gemcitabine and alkyl-lysophospholipid edelfosine. Eur J Pharm Biopharm 2019; 144:165-173. [PMID: 31546021 DOI: 10.1016/j.ejpb.2019.09.017] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2019] [Revised: 09/10/2019] [Accepted: 09/20/2019] [Indexed: 02/04/2023]
Abstract
Among anticancer nanomedicines, squalenoyl nanocomposites have obtained encouraging outcomes in a great variety of tumors. The prodrug squalenoyl-gemcitabine has been chosen in this study to construct a novel multidrug nanosystem in combination with edelfosine, an alkyl-lysophopholipid with proven anticancer activity. Given their amphiphilic nature, it was hypothesized that both anticancer compounds, with complementary molecular targets, could lead to the formation of a new multitherapy nanomedicine. Nanoassemblies were formulated by the nanoprecipitation method and characterized by dynamic light scattering, transmission electron microscopy and X-ray photoelectron spectroscopy. Because free edelfosine is highly hemolytic, hemolysis experiments were performed using human blood erythrocytes and nanoassemblies efficacy was evaluated in a patient-derived metastatic pediatric osteosarcoma cell line. It was observed that these molecules spontaneously self-assembled as stable and monodisperse nanoassemblies of 51 ± 1 nm in a surfactant/polymer free-aqueous suspension. Compared to squalenoyl-gemcitabine nanoassemblies, the combination of squalenoyl-gemcitabine with edelfosine resulted in smaller particle size and a new supramolecular conformation, with higher stability and drug content, and ameliorated antitumor profile.
Collapse
Affiliation(s)
- C Rodríguez-Nogales
- Chemistry and Pharmaceutical Technology Department, Universidad de Navarra, Pamplona 31008, Spain; Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona 31008, Spain
| | - V Sebastián
- Department of Chemical and Environmental Engineering & Institute of Nanoscience of Aragon (INA), University of Zaragoza, Zaragoza 50018, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine, CIBER-BBN, Madrid 28029, Spain
| | - S Irusta
- Department of Chemical and Environmental Engineering & Institute of Nanoscience of Aragon (INA), University of Zaragoza, Zaragoza 50018, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine, CIBER-BBN, Madrid 28029, Spain
| | - D Desmaële
- Institut Galien Paris-Sud, UMR CNRS 8612, Université Paris-Sud, Université Paris-Saclay, Châtenay-Malabry Cedex 92290, France
| | - P Couvreur
- Institut Galien Paris-Sud, UMR CNRS 8612, Université Paris-Sud, Université Paris-Saclay, Châtenay-Malabry Cedex 92290, France.
| | - M J Blanco-Prieto
- Chemistry and Pharmaceutical Technology Department, Universidad de Navarra, Pamplona 31008, Spain; Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona 31008, Spain.
| |
Collapse
|
9
|
Bhuckory S, Kays JC, Dennis AM. In Vivo Biosensing Using Resonance Energy Transfer. BIOSENSORS 2019; 9:E76. [PMID: 31163706 PMCID: PMC6628364 DOI: 10.3390/bios9020076] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/22/2019] [Revised: 05/20/2019] [Accepted: 05/27/2019] [Indexed: 01/05/2023]
Abstract
Solution-phase and intracellular biosensing has substantially enhanced our understanding of molecular processes foundational to biology and pathology. Optical methods are favored because of the low cost of probes and instrumentation. While chromatographic methods are helpful, fluorescent biosensing further increases sensitivity and can be more effective in complex media. Resonance energy transfer (RET)-based sensors have been developed to use fluorescence, bioluminescence, or chemiluminescence (FRET, BRET, or CRET, respectively) as an energy donor, yielding changes in emission spectra, lifetime, or intensity in response to a molecular or environmental change. These methods hold great promise for expanding our understanding of molecular processes not just in solution and in vitro studies, but also in vivo, generating information about complex activities in a natural, organismal setting. In this review, we focus on dyes, fluorescent proteins, and nanoparticles used as energy transfer-based optical transducers in vivo in mice; there are examples of optical sensing using FRET, BRET, and in this mammalian model system. After a description of the energy transfer mechanisms and their contribution to in vivo imaging, we give a short perspective of RET-based in vivo sensors and the importance of imaging in the infrared for reduced tissue autofluorescence and improved sensitivity.
Collapse
Affiliation(s)
- Shashi Bhuckory
- Department of Biomedical Engineering, Boston University, Boston, MA 02215, USA.
| | - Joshua C Kays
- Department of Biomedical Engineering, Boston University, Boston, MA 02215, USA.
| | - Allison M Dennis
- Department of Biomedical Engineering, Boston University, Boston, MA 02215, USA.
- Division of Materials Science and Engineering, Boston University, Boston, MA 02215, USA.
| |
Collapse
|
10
|
Mura S, Fattal E, Nicolas J. From poly(alkyl cyanoacrylate) to squalene as core material for the design of nanomedicines. J Drug Target 2019; 27:470-501. [PMID: 30720372 DOI: 10.1080/1061186x.2019.1579822] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
This review article covers the most important steps of the pioneering work of Patrick Couvreur and tries to shed light on his outstanding career that has been a source of inspiration for many decades. His discovery of biodegradable poly(alkyl cyanoacrylate) (PACA) nanoparticles (NPs) has opened large perspectives in nanomedicine. Indeed, NPs made from various types of alkyl cyanoacrylate monomers have been used in different applications, such as the treatment of intracellular infections or the treatment of multidrug resistant hepatocarcinoma. This latest application led to the Phase III clinical trial of Livatag®, a PACA nanoparticulate formulation of doxorubicin. Despite the success of PACA NPs, the development of a novel type of NP with higher drug loadings and lower burst release was tackled by the discovery of squalene-based nanomedicines where the drug is covalently linked to the lipid derivative and the resulting conjugate is self-assembled into NPs. This pioneering work was accompanied by a wide range of novel applications which mainly dealt with the management of unmet medical needs (e.g. pancreatic cancer, brain ischaemia and spinal cord injury).
Collapse
Affiliation(s)
- Simona Mura
- a Institut Galien Paris-Sud, UMR CNRS 8612, Faculté de Pharmacie, Université Paris-Sud, Université Paris-Saclay , Châtenay-Malabry , France
| | - Elias Fattal
- a Institut Galien Paris-Sud, UMR CNRS 8612, Faculté de Pharmacie, Université Paris-Sud, Université Paris-Saclay , Châtenay-Malabry , France
| | - Julien Nicolas
- a Institut Galien Paris-Sud, UMR CNRS 8612, Faculté de Pharmacie, Université Paris-Sud, Université Paris-Saclay , Châtenay-Malabry , France
| |
Collapse
|
11
|
Date T, Paul K, Singh N, Jain S. Drug-Lipid Conjugates for Enhanced Oral Drug Delivery. AAPS PharmSciTech 2019; 20:41. [PMID: 30610658 DOI: 10.1208/s12249-018-1272-0] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2018] [Accepted: 12/11/2018] [Indexed: 02/07/2023] Open
Abstract
Oral drug delivery route is one of the most convenient and extensively utilised routes for drug administration. But there exists class of drugs which exhibit poor bioavailability on oral drug administration. Designing of drug-lipid conjugates (DLCs) is one of the rationale strategy utilised in overcoming this challenge. This review extensively covers the various dimensions of drug modification using lipids to attain improved oral drug delivery. DLCs help in improving oral delivery by providing benefits like improved permeability, stability in gastric environment, higher drug loading in carriers, formation of self-assembled nanostructures, etc. The clinical effectiveness of DLCs is highlighted from available marketed drug products along with many DLCs in phase of clinical trials. Conclusively, this drug modification strategy can potentially help in augmenting oral drug delivery in future.
Collapse
|
12
|
Squalene versus cholesterol: Which is the best nanocarrier for the delivery to cells of the anticancer drug gemcitabine? CR CHIM 2018. [DOI: 10.1016/j.crci.2018.02.008] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
13
|
Tam YT, Huang C, Poellmann M, Kwon GS. Stereocomplex Prodrugs of Oligo(lactic acid) n-Gemcitabine in Poly(ethylene glycol)- block-poly(d,l-lactic acid) Micelles for Improved Physical Stability and Enhanced Antitumor Efficacy. ACS NANO 2018; 12:7406-7414. [PMID: 29957934 PMCID: PMC6071312 DOI: 10.1021/acsnano.8b04205] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
Abstract
Herein we demonstrate the formation of stereocomplex prodrugs of oligo(l-lactic acid) n-gemcitabine (o(LLA) n-GEM) and oligo(d-lactic acid) n-gemcitabine (o(DLA) n-GEM) for stable incorporation in poly(ethylene glycol)- block-poly(d,l-lactic acid) (PEG- b-PLA) micelles. O(LLA) n or o(DLA) n was attached at the amino group (4-( N)) of GEM via an amide linkage. When n = 10, a 1:1 mixture of o(LLA)10-GEM and o(DLA)10-GEM (o(L+DLA)10-GEM) was able to form a stereocomplex with a distinctive crystalline pattern. Degradation of o(L+DLA)10-GEM was driven by both backbiting conversion and esterase contribution, generating primarily o(L+DLA)1-GEM and GEM. O(L+DLA)10-GEM stably loaded in PEG- b-PLA micelles in the size range of 140-200 nm with an unexpected elongated morphology. The resulting micelles showed improved physical stability in aqueous media and inhibited backbiting conversion of o(L+DLA)10-GEM within micelles. Release of o(L+DLA)10-GEM from micelles was relatively slow, with a t1/2 at ca. 60 h. Furthermore, weekly administration of o(L+DLA)10-GEM micelles i.v. displayed potent antitumor activity in an A549 human non-small-cell lung carcinoma xenograft model. Thus, stereocomplexation of isotactic o(LLA) n and o(DLA) n acts as a potential prodrug strategy for improved stability and sustained drug release in PEG- b-PLA micelles.
Collapse
|
14
|
Cayre F, Mura S, Andreiuk B, Sobot D, Gouazou S, Desmaële D, Klymchenko AS, Couvreur P. In Vivo FRET Imaging to Predict the Risk Associated with Hepatic Accumulation of Squalene-Based Prodrug Nanoparticles. Adv Healthc Mater 2018; 7. [PMID: 29195020 DOI: 10.1002/adhm.201700830] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2017] [Revised: 10/05/2017] [Indexed: 12/23/2022]
Abstract
Förster resonance energy transfer (FRET) is used here for the first time to monitor the in vivo fate of nanoparticles made of the squalene-gemcitabine prodrug and two novel derivatives of squalene with the cyanine dyes 5.5 and 7.5, which behave as efficient FRET pair in the NIR region. Following intravenous administration, nanoparticles initially accumulate in the liver, then they show loss of their integrity within 2 h and clearance of the squalene bioconjugates is observed within 24 h. Such awareness is a key prerequisite before introduction into clinical settings.
Collapse
Affiliation(s)
- Fanny Cayre
- Institut Galien Paris-Sud; UMR 8612; CNRS; Univ Paris-Sud; Université Paris-Saclay; Faculté de Pharmacie; 5 rue Jean-Baptiste Clément F-92296 Châtenay-Malabry Cedex France
| | - Simona Mura
- Institut Galien Paris-Sud; UMR 8612; CNRS; Univ Paris-Sud; Université Paris-Saclay; Faculté de Pharmacie; 5 rue Jean-Baptiste Clément F-92296 Châtenay-Malabry Cedex France
| | - Bohdan Andreiuk
- Laboratoire de Biophotonique et Pharmacologie; UMR CNRS 7213; University of Strasbourg; 74 route du Rhin 67401 Illkirch Cedex France
- Organic Chemistry Department; Chemistry Faculty; Taras Shevchenko National University of Kyiv; 01601 Kyiv Ukraine
| | - Dunja Sobot
- Institut Galien Paris-Sud; UMR 8612; CNRS; Univ Paris-Sud; Université Paris-Saclay; Faculté de Pharmacie; 5 rue Jean-Baptiste Clément F-92296 Châtenay-Malabry Cedex France
| | - Sandrine Gouazou
- Institut Galien Paris-Sud; UMR 8612; CNRS; Univ Paris-Sud; Université Paris-Saclay; Faculté de Pharmacie; 5 rue Jean-Baptiste Clément F-92296 Châtenay-Malabry Cedex France
| | - Didier Desmaële
- Institut Galien Paris-Sud; UMR 8612; CNRS; Univ Paris-Sud; Université Paris-Saclay; Faculté de Pharmacie; 5 rue Jean-Baptiste Clément F-92296 Châtenay-Malabry Cedex France
| | - Andrey S. Klymchenko
- Laboratoire de Biophotonique et Pharmacologie; UMR CNRS 7213; University of Strasbourg; 74 route du Rhin 67401 Illkirch Cedex France
| | - Patrick Couvreur
- Institut Galien Paris-Sud; UMR 8612; CNRS; Univ Paris-Sud; Université Paris-Saclay; Faculté de Pharmacie; 5 rue Jean-Baptiste Clément F-92296 Châtenay-Malabry Cedex France
| |
Collapse
|
15
|
Babič A, Herceg V, Bastien E, Lassalle HP, Bezdetnaya L, Lange N. 5-Aminolevulinic Acid-Squalene Nanoassemblies for Tumor Photodetection and Therapy: In Vitro Studies. NANOSCALE RESEARCH LETTERS 2018; 13:10. [PMID: 29327259 PMCID: PMC5764903 DOI: 10.1186/s11671-017-2408-y] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/28/2017] [Accepted: 12/10/2017] [Indexed: 05/22/2023]
Abstract
Protoporphyrin IX (PpIX) as natural photosensitizer derived from administration of 5-aminolevulinic acid (5-ALA) has found clinical use for photodiagnosis and photodynamic therapy of several cancers. However, broader use of 5-ALA in oncology is hampered by its charge and polarity that result in its reduced capacity for passing biological barriers and reaching the tumor tissue. Advanced drug delivery platforms are needed to improve the biodistribution of 5-ALA. Here, we report a new approach for the delivery of 5-ALA. Squalenoylation strategy was used to covalently conjugate 5-ALA to squalene, a natural precursor of cholesterol. 5-ALA-SQ nanoassemblies were formed by self-assembly in water. The nanoassemblies were monodisperse with average size of 70 nm, polydispersity index of 0.12, and ζ-potential of + 36 mV. They showed good stability over several weeks. The drug loading of 5-ALA was very high at 26%. In human prostate cancer cells PC3 and human glioblastoma cells U87MG, PpIX production was monitored in vitro upon the incubation with nanoassemblies. They were more efficient in generating PpIX-induced fluorescence in cancer cells compared to 5-ALA-Hex at 1.0 to 3.3 mM at short and long incubation times. Compared to 5-ALA, they showed superior fluorescence performance at 4 h which was diminished at 24 h. 5-ALA-SQ presents a novel nano-delivery platform with great potential for the systemic administration of 5-ALA.
Collapse
Affiliation(s)
- Andrej Babič
- School of Pharmaceutical Sciences, University of Geneva, Rue Michel Servet 1, 1211, Geneva 4, Switzerland.
- School of Pharmaceutical Sciences, University of Lausanne, Lausanne, Switzerland.
| | - V Herceg
- School of Pharmaceutical Sciences, University of Geneva, Rue Michel Servet 1, 1211, Geneva 4, Switzerland
- School of Pharmaceutical Sciences, University of Lausanne, Lausanne, Switzerland
| | - E Bastien
- Centre de Recherche en Automatique de Nancy (CRAN), CNRS UMR 7039 (Centre National de la Recherche Scientifique), Université de Lorraine, Campus Sciences, Vandœuvre-lès-Nancy, France
- Research Department, Institut de Cancérologie de Lorraine, Avenue de Bourgogne, 54519, Vandœuvre-lès-Nancy, France
| | - H-P Lassalle
- Centre de Recherche en Automatique de Nancy (CRAN), CNRS UMR 7039 (Centre National de la Recherche Scientifique), Université de Lorraine, Campus Sciences, Vandœuvre-lès-Nancy, France
- Research Department, Institut de Cancérologie de Lorraine, Avenue de Bourgogne, 54519, Vandœuvre-lès-Nancy, France
| | - L Bezdetnaya
- Centre de Recherche en Automatique de Nancy (CRAN), CNRS UMR 7039 (Centre National de la Recherche Scientifique), Université de Lorraine, Campus Sciences, Vandœuvre-lès-Nancy, France
- Research Department, Institut de Cancérologie de Lorraine, Avenue de Bourgogne, 54519, Vandœuvre-lès-Nancy, France
| | - Norbert Lange
- School of Pharmaceutical Sciences, University of Geneva, Rue Michel Servet 1, 1211, Geneva 4, Switzerland.
- School of Pharmaceutical Sciences, University of Lausanne, Lausanne, Switzerland.
| |
Collapse
|
16
|
Sobot D, Mura S, Rouquette M, Vukosavljevic B, Cayre F, Buchy E, Pieters G, Garcia-Argote S, Windbergs M, Desmaële D, Couvreur P. Circulating Lipoproteins: A Trojan Horse Guiding Squalenoylated Drugs to LDL-Accumulating Cancer Cells. Mol Ther 2017; 25:1596-1605. [PMID: 28606375 PMCID: PMC5498828 DOI: 10.1016/j.ymthe.2017.05.016] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2016] [Revised: 05/23/2017] [Accepted: 05/23/2017] [Indexed: 11/30/2022] Open
Abstract
Selective delivery of anticancer drugs to rapidly growing cancer cells can be achieved by taking advantage of their high receptor-mediated uptake of low-density lipoproteins (LDLs). Indeed, we have recently discovered that nanoparticles made of the squalene derivative of the anticancer agent gemcitabine (SQGem) strongly interacted with the LDLs in the human blood. In the present study, we showed both in vitro and in vivo that such interaction led to the preferential accumulation of SQGem in cancer cells (MDA-MB-231) with high LDL receptor expression. As a result, an improved pharmacological activity has been observed in MDA-MB-231 tumor-bearing mice, an experimental model with a low sensitivity to gemcitabine. Accordingly, we proved that the use of squalene moieties not only induced the gemcitabine insertion into lipoproteins, but that it could also be exploited to indirectly target cancer cells in vivo.
Collapse
MESH Headings
- Adenocarcinoma/genetics
- Adenocarcinoma/pathology
- Adenocarcinoma/therapy
- Animals
- Antineoplastic Agents/chemistry
- Antineoplastic Agents/pharmacology
- Breast Neoplasms/genetics
- Breast Neoplasms/pathology
- Breast Neoplasms/therapy
- Cell Line, Tumor
- Deoxycytidine/analogs & derivatives
- Deoxycytidine/chemistry
- Deoxycytidine/pharmacology
- Drug Carriers
- Female
- Gene Expression Regulation, Neoplastic
- Humans
- Lipoproteins, LDL/chemistry
- Lipoproteins, LDL/metabolism
- Mice
- Mice, Inbred BALB C
- Mice, Inbred C57BL
- Mice, Nude
- Mice, SCID
- Nanoparticles/administration & dosage
- Nanoparticles/chemistry
- Receptors, LDL/genetics
- Receptors, LDL/metabolism
- Squalene/chemistry
- Tumor Burden/drug effects
- Xenograft Model Antitumor Assays
- Gemcitabine
Collapse
Affiliation(s)
- Dunja Sobot
- Institut Galien Paris-Sud, UMR 8612, CNRS, University Paris-Sud, Université Paris-Saclay, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, 92296 Châtenay-Malabry Cedex, France
| | - Simona Mura
- Institut Galien Paris-Sud, UMR 8612, CNRS, University Paris-Sud, Université Paris-Saclay, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, 92296 Châtenay-Malabry Cedex, France
| | - Marie Rouquette
- Institut Galien Paris-Sud, UMR 8612, CNRS, University Paris-Sud, Université Paris-Saclay, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, 92296 Châtenay-Malabry Cedex, France
| | - Branko Vukosavljevic
- Department of Drug Delivery, Helmholtz Institute for Pharmaceutical Research Saarland, Helmholtz Center for Infection Research, Campus E8 1, 66123 Saarbruecken, Germany
| | - Fanny Cayre
- Institut Galien Paris-Sud, UMR 8612, CNRS, University Paris-Sud, Université Paris-Saclay, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, 92296 Châtenay-Malabry Cedex, France
| | - Eric Buchy
- Institut Galien Paris-Sud, UMR 8612, CNRS, University Paris-Sud, Université Paris-Saclay, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, 92296 Châtenay-Malabry Cedex, France
| | - Grégory Pieters
- SCBM, CEA, Université Paris Saclay, LabEx LERMIT, 91191 Gif-sur-Yvette, France
| | | | - Maike Windbergs
- Department of Drug Delivery, Helmholtz Institute for Pharmaceutical Research Saarland, Helmholtz Center for Infection Research, Campus E8 1, 66123 Saarbruecken, Germany; Institute of Pharmaceutical Technology, Buchmann Institute for Molecular Life Sciences, Goethe University, Max-von-Laue-Strasse 15, 60438 Frankfurt am Main, Germany
| | - Didier Desmaële
- Institut Galien Paris-Sud, UMR 8612, CNRS, University Paris-Sud, Université Paris-Saclay, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, 92296 Châtenay-Malabry Cedex, France
| | - Patrick Couvreur
- Institut Galien Paris-Sud, UMR 8612, CNRS, University Paris-Sud, Université Paris-Saclay, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, 92296 Châtenay-Malabry Cedex, France.
| |
Collapse
|
17
|
Valdes S, Naguib YW, Finch RA, Baze WB, Jolly CA, Cui Z. Preclinical Evaluation of the Short-Term Toxicity of 4-(N)-Docosahexaenoyl 2´, 2´- Difluorodeoxycytidine (DHA-dFdC). Pharm Res 2017; 34:1224-1232. [PMID: 28352993 PMCID: PMC5488709 DOI: 10.1007/s11095-017-2139-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2016] [Accepted: 03/02/2017] [Indexed: 11/28/2022]
Abstract
PURPOSE This study was designed to test the short-term toxicity of DHA-dFdC in a mouse model and its efficacy in a mouse model of leukemia at or below its repeat-dose maximum tolerated dose (RD-MTD). METHOD A repeat-dose dose-ranging toxicity study was designed to determine the tolerability of DHA-dFdC when administered to DBA/2 mice by intravenous (i.v.) injection on a repeat-dose schedule (i.e. injections on days 0, 3, 7, 10, and 13). In order to determine the effect of a lethal dose of DHA-dFdC, mice were injected i.v. with three doses of DHA-dFdC at 100 mg/kg on days 0, 3, and 5 (i.e. a lethal-RD). The body weight of mice was recorded two or three times a week. At the end of the study, major organs (i.e. heart, liver, spleen, kidneys, lung, and pancreas) of mice that received the lethal-RD or RD-MTD were weighed, and blood samples were collected for analyses. Finally, DHA-dFdC was i.v. injected into DBA/2 mice with syngeneic L1210 mouse leukemia cells to evaluate its efficacy at or below RD-MTD. RESULTS The RD-MTD of DHA-dFdC is 50 mg/kg. At 100 mg/kg, a lethal-RD, DHA-dFdC decreases the weights of mouse spleen and liver and significantly affected certain blood parameters (i.e. white blood cells, lymphocytes, eosinophils, and neutrophil segmented). At or below its RD-MTD, DHA-dFdC significantly prolonged the survival of L1210 leukemia-bearing mice. CONCLUSION DHA-dFdC has dose-dependent toxicity, affecting mainly spleen at a lethal-RD. At or below its RD-MTD, DHA-dFdC is effective against leukemia in a mouse model.
Collapse
Affiliation(s)
- Solange Valdes
- Pharmaceutics Division, College of Pharmacy, The University of Texas at Austin, Austin, Texas, 78712, USA
| | - Youssef W Naguib
- Pharmaceutics Division, College of Pharmacy, The University of Texas at Austin, Austin, Texas, 78712, USA
| | - Rick A Finch
- Department of Veterinary Sciences, Michale E. Keeling Center for Comparative Medicine and Research, University of Texas M.D. Anderson Cancer Center, Bastrop, Texas, 78602, USA
| | - Wallace B Baze
- Department of Veterinary Sciences, Michale E. Keeling Center for Comparative Medicine and Research, University of Texas M.D. Anderson Cancer Center, Bastrop, Texas, 78602, USA
| | - Christopher A Jolly
- Department of Nutritional Sciences, College of Natural Sciences, The University of Texas at Austin, Austin, Texas, 78712, USA
| | - Zhengrong Cui
- Pharmaceutics Division, College of Pharmacy, The University of Texas at Austin, Austin, Texas, 78712, USA.
| |
Collapse
|
18
|
Sobot D, Mura S, Yesylevskyy SO, Dalbin L, Cayre F, Bort G, Mougin J, Desmaële D, Lepetre-Mouelhi S, Pieters G, Andreiuk B, Klymchenko AS, Paul JL, Ramseyer C, Couvreur P. Conjugation of squalene to gemcitabine as unique approach exploiting endogenous lipoproteins for drug delivery. Nat Commun 2017; 8:15678. [PMID: 28555624 PMCID: PMC5459998 DOI: 10.1038/ncomms15678] [Citation(s) in RCA: 71] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2016] [Accepted: 04/18/2017] [Indexed: 12/20/2022] Open
Abstract
Once introduced in the organism, the interaction of nanoparticles with various biomolecules strongly impacts their fate. Here we show that nanoparticles made of the squalene derivative of gemcitabine (SQGem) interact with lipoproteins (LPs), indirectly enabling the targeting of cancer cells with high LP receptors expression. In vitro and in vivo experiments reveal preeminent affinity of the squalene-gemcitabine bioconjugates towards LP particles with the highest cholesterol content and in silico simulations further display their incorporation into the hydrophobic core of LPs. To the best of our knowledge, the use of squalene to induce drug insertion into LPs for indirect cancer cell targeting is a novel concept in drug delivery. Interestingly, not only SQGem but also other squalene derivatives interact similarly with lipoproteins while such interaction is not observed with liposomes. The conjugation to squalene represents a versatile platform that would enable efficient drug delivery by simply exploiting endogenous lipoproteins. The interaction of nanoparticles with a range of biomolecules once they have been injected within the body can affect their performance. Here, the authors demonstrate that squalene nanomaterials conjugated with anticancer drugs can interact with lipoproteins and can be used to target cancer cells.
Collapse
Affiliation(s)
- Dunja Sobot
- Institut Galien Paris-Sud, UMR 8612, CNRS, Univ Paris-Sud, Université Paris-Saclay, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, F-92296 Châtenay-Malabry Cedex, France
| | - Simona Mura
- Institut Galien Paris-Sud, UMR 8612, CNRS, Univ Paris-Sud, Université Paris-Saclay, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, F-92296 Châtenay-Malabry Cedex, France
| | - Semen O Yesylevskyy
- Department of Physics of Biological Systems, Institute of Physics of the National Academy of Sciences of Ukraine, Prospect Nauky 46, 03028 Kyiv, Ukraine
| | - Laura Dalbin
- Institut Galien Paris-Sud, UMR 8612, CNRS, Univ Paris-Sud, Université Paris-Saclay, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, F-92296 Châtenay-Malabry Cedex, France
| | - Fanny Cayre
- Institut Galien Paris-Sud, UMR 8612, CNRS, Univ Paris-Sud, Université Paris-Saclay, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, F-92296 Châtenay-Malabry Cedex, France
| | - Guillaume Bort
- Institut Galien Paris-Sud, UMR 8612, CNRS, Univ Paris-Sud, Université Paris-Saclay, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, F-92296 Châtenay-Malabry Cedex, France
| | - Julie Mougin
- Institut Galien Paris-Sud, UMR 8612, CNRS, Univ Paris-Sud, Université Paris-Saclay, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, F-92296 Châtenay-Malabry Cedex, France
| | - Didier Desmaële
- Institut Galien Paris-Sud, UMR 8612, CNRS, Univ Paris-Sud, Université Paris-Saclay, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, F-92296 Châtenay-Malabry Cedex, France
| | - Sinda Lepetre-Mouelhi
- Institut Galien Paris-Sud, UMR 8612, CNRS, Univ Paris-Sud, Université Paris-Saclay, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, F-92296 Châtenay-Malabry Cedex, France
| | - Grégory Pieters
- CEA Saclay, iBiTecS-S/SCBM, Labex LERMIT, 91191 Gif-sur-Yvette, France
| | - Bohdan Andreiuk
- Laboratoire de Biophotonique et Pharmacologie, UMR CNRS 7213, University of Strasbourg, 74 route du Rhin, 67401 Illkirch Cedex, France.,Department of Organic Chemistry, Chemistry Faculty, Taras Shevchenko National University of Kyiv, 01601 Kyiv, Ukraine
| | - Andrey S Klymchenko
- Laboratoire de Biophotonique et Pharmacologie, UMR CNRS 7213, University of Strasbourg, 74 route du Rhin, 67401 Illkirch Cedex, France
| | - Jean-Louis Paul
- AP-HP, Hôpital Européen Georges Pompidou, Service de Biochimie, 75015 Paris, France.,Lip(Sys)2, Athérosclérose: homéostasie et trafic du cholestérol des macrophages, Univ Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France
| | - Christophe Ramseyer
- Laboratoire Chrono Environnement UMR CNRS 6249, Université de Bourgogne Franche-Comté, 16 route de Gray, 25030 Besançon Cedex, France
| | - Patrick Couvreur
- Institut Galien Paris-Sud, UMR 8612, CNRS, Univ Paris-Sud, Université Paris-Saclay, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, F-92296 Châtenay-Malabry Cedex, France
| |
Collapse
|
19
|
Abstract
Lipid-drug conjugates (LDCs) are drug molecules that have been covalently modified with lipids. The conjugation of lipids to drug molecules increases lipophilicity and also changes other properties of drugs. The conjugates demonstrate several advantages including improved oral bioavailability, improved targeting to the lymphatic system, enhanced tumor targeting, and reduced toxicity. Based on the chemical nature of drugs and lipids, various conjugation strategies and chemical linkers can be utilized to synthesize LDCs. Linkers and/or conjugation methods determine how drugs are released from LDCs and are critical for the optimal performance of LDCs. In this review, different lipids used for preparing LDCs and various conjugation strategies are summarized. Although LDCs can be administered without a delivery carrier, most of them are loaded into appropriate delivery systems. The lipid moiety in the conjugates can significantly enhance drug loading into hydrophobic components of delivery carriers and thus generate formulations with high drug loading and superior stability. Different delivery carriers such as emulsions, liposomes, micelles, lipid nanoparticles, and polymer nanoparticles are also discussed in this review.
Collapse
Affiliation(s)
- Danielle Irby
- Department of Pharmaceutical Sciences, School of Pharmacy, Hampton University , Hampton, Virginia 23668, United States
| | - Chengan Du
- Department of Pharmaceutical Sciences, School of Pharmacy, Hampton University , Hampton, Virginia 23668, United States
| | - Feng Li
- Department of Pharmaceutical Sciences, School of Pharmacy, Hampton University , Hampton, Virginia 23668, United States
| |
Collapse
|
20
|
Mura S, Buchy E, Askin G, Cayre F, Mougin J, Gouazou S, Sobot D, Valetti S, Stella B, Desmaele D, Couvreur P. In vitro investigation of multidrug nanoparticles for combined therapy with gemcitabine and a tyrosine kinase inhibitor: Together is not better. Biochimie 2016; 130:4-13. [DOI: 10.1016/j.biochi.2016.08.003] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2016] [Accepted: 08/07/2016] [Indexed: 11/26/2022]
|
21
|
Naguib YW, Lansakara-P D, Lashinger LM, Rodriguez BL, Valdes S, Niu M, Aldayel AM, Peng L, Hursting SD, Cui Z. Synthesis, Characterization, and In Vitro and In Vivo Evaluations of 4-(N)-Docosahexaenoyl 2', 2'-Difluorodeoxycytidine with Potent and Broad-Spectrum Antitumor Activity. Neoplasia 2016; 18:33-48. [PMID: 26806350 PMCID: PMC5965255 DOI: 10.1016/j.neo.2015.11.012] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2015] [Revised: 11/11/2015] [Accepted: 11/11/2015] [Indexed: 12/28/2022] Open
Abstract
In this study, a new compound, 4-(N)-docosahexaenoyl 2′, 2′-difluorodeoxycytidine (DHA-dFdC), was synthesized and characterized. Its antitumor activity was evaluated in cell culture and in mouse models of pancreatic cancer. DHA-dFdC is a poorly soluble, pale yellow waxy solid, with a molecular mass of 573.3 Da and a melting point of about 96°C. The activation energy for the degradation of DHA-dFdC in an aqueous Tween 80–based solution is 12.86 kcal/mol, whereas its stability is significantly higher in the presence of vitamin E. NCI-60 DTP Human Tumor Cell Line Screening revealed that DHA-dFdC has potent and broad-spectrum antitumor activity, especially in leukemia, renal, and central nervous system cancer cell lines. In human and murine pancreatic cancer cell lines, the IC50 value of DHA-dFdC was up to 105-fold lower than that of dFdC. The elimination of DHA-dFdC in mouse plasma appeared to follow a biexponential model, with a terminal phase t1/2 of about 58 minutes. DHA-dFdC significantly extended the survival of genetically engineered mice that spontaneously develop pancreatic ductal adenocarcinoma. In nude mice with subcutaneously implanted human Panc-1 pancreatic tumors, the antitumor activity of DHA-dFdC was significantly stronger than the molar equivalent of dFdC alone, DHA alone, or the physical mixture of them (1:1, molar ratio). DHA-dFdC also significantly inhibited the growth of Panc-1 tumors orthotopically implanted in the pancreas of nude mice, whereas the molar equivalent dose of dFdC alone did not show any significant activity. DHA-dFdC is a promising compound for the potential treatment of cancers in organs such as the pancreas.
Collapse
Affiliation(s)
- Youssef W Naguib
- Pharmaceutics Division, College of Pharmacy, The University of Texas at Austin, Austin, TX 78712
| | - Dharmika Lansakara-P
- Pharmaceutics Division, College of Pharmacy, The University of Texas at Austin, Austin, TX 78712
| | - Laura M Lashinger
- Department of Nutritional Sciences, College of Natural Sciences, The University of Texas at Austin, Austin, TX 78712
| | - B Leticia Rodriguez
- Pharmaceutics Division, College of Pharmacy, The University of Texas at Austin, Austin, TX 78712
| | - Solange Valdes
- Pharmaceutics Division, College of Pharmacy, The University of Texas at Austin, Austin, TX 78712
| | - Mengmeng Niu
- Pharmaceutics Division, College of Pharmacy, The University of Texas at Austin, Austin, TX 78712
| | - Abdulaziz M Aldayel
- Pharmaceutics Division, College of Pharmacy, The University of Texas at Austin, Austin, TX 78712
| | - Lan Peng
- Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, TX 75390
| | - Stephen D Hursting
- Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC 27599
| | - Zhengrong Cui
- Pharmaceutics Division, College of Pharmacy, The University of Texas at Austin, Austin, TX 78712.
| |
Collapse
|
22
|
Gaudin A, Song E, King AR, Saucier-Sawyer JK, Bindra R, Desmaële D, Couvreur P, Saltzman WM. PEGylated squalenoyl-gemcitabine nanoparticles for the treatment of glioblastoma. Biomaterials 2016; 105:136-144. [PMID: 27521616 DOI: 10.1016/j.biomaterials.2016.07.037] [Citation(s) in RCA: 44] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2016] [Revised: 07/27/2016] [Accepted: 07/29/2016] [Indexed: 11/25/2022]
Abstract
New treatments for glioblastoma multiforme (GBM) are desperately needed, as GBM prognosis remains poor, mainly due to treatment resistance, poor distribution of therapeutics in the tumor tissue, and fast metabolism of chemotherapeutic drugs in the brain extracellular space. Convection-enhanced delivery (CED) of nanoparticles (NPs) has been shown to improve the delivery of chemotherapeutic drugs to the tumor bed, providing sustained release, and enhancing survival of animals with intracranial tumors. Here we administered gemcitabine, a nucleoside analog used as a first line treatment for a wide variety of extracranial solid tumors, within squalene-based NPs using CED, to overcome the above-mentioned challenges of GBM treatment. Small percentages of poly(ethylene) glycol (PEG) dramatically enhanced the distribution of squalene-gemcitabine nanoparticles (SQ-Gem NPs) in healthy animals and tumor-bearing animals after administration by CED. When tested in an orthotopic model of GBM, SQ-Gem-PEG NPs demonstrated significantly improved therapeutic efficacy compared to free gemcitabine, both as a chemotherapeutic drug and as a radiosensitizer. Furthermore, MR contrast agents were incorporated into the SQ-Gem-PEG NP formulation, providing a way to non-invasively track the NPs during infusion.
Collapse
Affiliation(s)
- Alice Gaudin
- Department of Biomedical Engineering, Yale University, New Haven, CT, 06511, USA
| | - Eric Song
- Department of Biomedical Engineering, Yale University, New Haven, CT, 06511, USA
| | - Amanda R King
- Department of Biomedical Engineering, Yale University, New Haven, CT, 06511, USA
| | | | - Ranjit Bindra
- Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT, 06511, USA
| | - Didier Desmaële
- Institut Galien Paris-Sud, UMR CNRS 8612, University Paris-Sud XI, Châtenay-Malabry, 92290, France
| | - Patrick Couvreur
- Institut Galien Paris-Sud, UMR CNRS 8612, University Paris-Sud XI, Châtenay-Malabry, 92290, France
| | - W Mark Saltzman
- Department of Biomedical Engineering, Yale University, New Haven, CT, 06511, USA.
| |
Collapse
|
23
|
Fumagalli G, Marucci C, Christodoulou MS, Stella B, Dosio F, Passarella D. Self-assembly drug conjugates for anticancer treatment. Drug Discov Today 2016; 21:1321-9. [DOI: 10.1016/j.drudis.2016.06.018] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2016] [Revised: 05/10/2016] [Accepted: 06/15/2016] [Indexed: 12/28/2022]
|
24
|
Buchy E, Vukosavljevic B, Windbergs M, Sobot D, Dejean C, Mura S, Couvreur P, Desmaële D. Synthesis of a deuterated probe for the confocal Raman microscopy imaging of squalenoyl nanomedicines. Beilstein J Org Chem 2016; 12:1127-35. [PMID: 27559365 PMCID: PMC4979966 DOI: 10.3762/bjoc.12.109] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2016] [Accepted: 05/19/2016] [Indexed: 01/07/2023] Open
Abstract
The synthesis of ω-di-(trideuteromethyl)-trisnorsqualenic acid has been achieved from natural squalene. The synthesis features the use of a Shapiro reaction of acetone-d 6 trisylhydrazone as a key step to implement the terminal isopropylidene-d 6 moiety. The obtained squalenic acid-d 6 has been coupled to gemcitabine to provide the deuterated analogue of squalenoyl gemcitabine, a powerful anticancer agent endowed with self-assembling properties. The Raman spectra of both deuterated and non-deuterated squalenoyl gemcitabine nanoparticles displayed significant Raman scattering signals. They revealed no differences except from the deuterium peak patterns in the silent spectral region of cells. This paves the way for label-free intracellular trafficking studies of squalenoyl nanomedicines.
Collapse
Affiliation(s)
- Eric Buchy
- Institut Galien (UMR CNRS 8612) Faculté de Pharmacie, Université Paris-Sud, 5, rue Jean-Baptiste Clément, 92296 Châtenay-Malabry, France
| | - Branko Vukosavljevic
- Department of Drug Delivery, Helmholtz Centre for Infection Research and Helmholtz Institute for Pharmaceutical Research Saarland, Campus E8.1, 66123 Saarbruecken, Germany
- Biopharmaceutics and Pharmaceutical Technology, Saarland University, Campus A 4.1, 66123 Saarbruecken, Germany
| | - Maike Windbergs
- Department of Drug Delivery, Helmholtz Centre for Infection Research and Helmholtz Institute for Pharmaceutical Research Saarland, Campus E8.1, 66123 Saarbruecken, Germany
- Biopharmaceutics and Pharmaceutical Technology, Saarland University, Campus A 4.1, 66123 Saarbruecken, Germany
| | - Dunja Sobot
- Institut Galien (UMR CNRS 8612) Faculté de Pharmacie, Université Paris-Sud, 5, rue Jean-Baptiste Clément, 92296 Châtenay-Malabry, France
| | - Camille Dejean
- BIOCIS (UMR CNRS 8076) Faculté de Pharmacie, Université Paris-Sud, 5, rue Jean-Baptiste Clément, 92296 Châtenay-Malabry, France
| | - Simona Mura
- Institut Galien (UMR CNRS 8612) Faculté de Pharmacie, Université Paris-Sud, 5, rue Jean-Baptiste Clément, 92296 Châtenay-Malabry, France
| | - Patrick Couvreur
- Institut Galien (UMR CNRS 8612) Faculté de Pharmacie, Université Paris-Sud, 5, rue Jean-Baptiste Clément, 92296 Châtenay-Malabry, France
| | - Didier Desmaële
- Institut Galien (UMR CNRS 8612) Faculté de Pharmacie, Université Paris-Sud, 5, rue Jean-Baptiste Clément, 92296 Châtenay-Malabry, France
| |
Collapse
|
25
|
Gaudin A, Andrieux K, Couvreur P. Nanomedicines and stroke: Toward translational research. J Drug Deliv Sci Technol 2015. [DOI: 10.1016/j.jddst.2015.07.018] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
26
|
Saha D, Testard F, Grillo I, Zouhiri F, Desmaele D, Radulescu A, Desert S, Brulet A, Couvreur P, Spalla O. The role of solvent swelling in the self-assembly of squalene based nanomedicines. SOFT MATTER 2015; 11:4173-4179. [PMID: 25873336 DOI: 10.1039/c5sm00592b] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Squalene based nanoparticles obtained via nanoprecipitation are promising candidates as efficient anti-cancer drugs. In order to highlight their preparation process and to facilitate further clinical translation, the present study enlightens the paramount role of the solvent in the formation of these nanomedicines. Three different squalene-based nanoparticles, i.e. squalenic acid, deoxycytidine squalene and gemcitabine squalene, have been investigated before and after organic solvent evaporation. Size and structural analysis by Small Angle Neutron Scattering revealed that droplets' size was uniquely controlled by the solvent composition (ethanol-water), which evolved during their gradual formation. The particles were preferably swollen by water and the swelling increased when less ethanol was present. Either coalescence or fragmentation was observed depending on the increase or decrease of the ethanol content, supporting an equilibrium control of the size. Moreover, a high water swelling was observed for the three local organization of the nanodroplets (hexagonal for gemcitabine squalene, cubic for deoxycytidine and not structured for squalenic acid) and could be the source of the previously reported efficiency of related anti-cancer squalene based nanomedicines.
Collapse
Affiliation(s)
- Debasish Saha
- CEA Saclay, DSM/IRAMIS/NIMBE/LIONS, UMR CEA/CNRS 3299, 91191 Gif sur Yvette, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Caizhen G, Yan G, Ronron C, Lirong Y, Panpan C, Xuemei H, Yuanbiao Q, Qingshan L. Zirconium phosphatidylcholine-based nanocapsules as an in vivo degradable drug delivery system of MAP30, a momordica anti-HIV protein. Int J Pharm 2015; 483:188-99. [PMID: 25681721 DOI: 10.1016/j.ijpharm.2015.02.021] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2014] [Accepted: 02/10/2015] [Indexed: 01/24/2023]
Abstract
An essential in vivo drug delivery system of a momordica anti-HIV protein, MAP30, was developed through encapsulating in chemically synthesized matrices of zirconium egg- and soy-phosphatidylcholines, abbreviated to Zr/EPC and Zr/SPC, respectively. Matrices were characterized by transmission electron microscopy and powder X-ray diffractometry studies. Zr/EPC granule at an approximate diameter of 69.43±7.78 nm was a less efficient encapsulator than the granule of Zr/SPC. Interlayer spacing of the matrices encapsulating MAP30 increased from 8.8 and 9.7 Å to 7.4 and 7.9 nm, respectively. In vivo kinetics on degradation and protein release was performed by analyzing the serum sampling of intravenously injected SPF chickens. The first order and biphasic variations were obtained for in vivo kinetics using equilibrium dialysis. Antimicrobial and anti-HIV assays yielded greatly decreased MIC50 and EC50 values of nanoformulated MAP30. An acute toxicity of MAP30 encapsulated in Zr/EPC occurred at a single intravenous dose above 14.24 mg/kg bw in NIH/KM/ICR mice. The folding of MAP30 from Zr/EPC sustained in vivo chickens for more than 8 days in high performance liquid chromatography assays. These matrices could protect MAP30 efficiently with strong structure retention, lowered toxicity and prolonged in vivo life.
Collapse
Affiliation(s)
- Guo Caizhen
- Department of Bioscience, Luliang University, Shanxi 033001, PR China
| | - Gao Yan
- School of Pharmaceutical Sciences, Shanxi Medical University, Shanxi 030001, PR China
| | - Chang Ronron
- School of Pharmaceutical Sciences, Shanxi Medical University, Shanxi 030001, PR China
| | - Yang Lirong
- Department of Chemical and Biological Engineering, Zhejiang University, Zhejiang 310027, PR China
| | - Chu Panpan
- Department of Bioscience, Luliang University, Shanxi 033001, PR China
| | - Hu Xuemei
- Department of Chemistry and Chemical Engineering, Luliang University, Shanxi 033001, PR China
| | - Qiao Yuanbiao
- Graduate Institute of Pharmaceutical Chemistry, Luliang University, Shanxi 033001, PR China.
| | - Li Qingshan
- School of Pharmaceutical Sciences, Shanxi Medical University, Shanxi 030001, PR China.
| |
Collapse
|
28
|
Mura S, Bui DT, Couvreur P, Nicolas J. Lipid prodrug nanocarriers in cancer therapy. J Control Release 2015; 208:25-41. [PMID: 25617724 DOI: 10.1016/j.jconrel.2015.01.021] [Citation(s) in RCA: 71] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2014] [Revised: 01/12/2015] [Accepted: 01/20/2015] [Indexed: 10/24/2022]
Abstract
Application of nanotechnology in the medical field (i.e., nanomedicine) plays an important role in the development of novel drug delivery methods. Nanoscale drug delivery systems can indeed be customized with specific functionalities in order to improve the efficacy of the treatments. However, despite the progresses of the last decades, nanomedicines still face important obstacles related to: (i) the physico-chemical properties of the drug moieties which may reduce the total amount of loaded drug; (ii) the rapid and uncontrolled release (i.e., burst release) of the encapsulated drug after administration and (iii) the instability of the drug in biological media where a fast transformation into inactive metabolites can occur. As an alternative strategy to alleviate these drawbacks, the prodrug approach has found wide application. The covalent modification of a drug molecule into an inactive precursor from which the drug will be freed after administration offers several benefits such as: (i) a sustained drug release (mediated by chemical or enzymatic hydrolysis of the linkage between the drug-moiety and its promoiety); (ii) an increase of the drug chemical stability and solubility and, (iii) a reduced toxicity before the metabolization occurs. Lipids have been widely used as building blocks for the design of various prodrugs. Interestingly enough, these lipid-derivatized drugs can be delivered through a nanoparticulate form due to their ability to self-assemble and/or to be incorporated into lipid/polymer matrices. Among the several prodrugs developed so far, this review will focus on the main achievements in the field of lipid-based prodrug nanocarriers designed to improve the efficacy of anticancer drugs. Gemcitabine (Pubchem CID: 60750); 5-fluorouracil (Pubchem CID: 3385); Doxorubicin (Pubchem CID: 31703); Docetaxel (Pubchem CID: 148124); Methotrexate (Pubchem CID: 126941); Paclitaxel (Pubchem CID: 36314).
Collapse
Affiliation(s)
- Simona Mura
- Institut Galien Paris-Sud, UMR CNRS 8612, Univ Paris-Sud, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, F-92296 Châtenay-Malabry Cedex, France.
| | - Duc Trung Bui
- Institut Galien Paris-Sud, UMR CNRS 8612, Univ Paris-Sud, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, F-92296 Châtenay-Malabry Cedex, France
| | - Patrick Couvreur
- Institut Galien Paris-Sud, UMR CNRS 8612, Univ Paris-Sud, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, F-92296 Châtenay-Malabry Cedex, France
| | - Julien Nicolas
- Institut Galien Paris-Sud, UMR CNRS 8612, Univ Paris-Sud, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, F-92296 Châtenay-Malabry Cedex, France.
| |
Collapse
|
29
|
Bekkara-Aounallah F, Ambike A, Gref R, Couvreur P, Rosilio V. Interfacial behavior of PEGylated lipids and their effect on the stability of squalenoyl-drug nanoassemblies. Int J Pharm 2014; 471:75-82. [DOI: 10.1016/j.ijpharm.2014.04.072] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2014] [Revised: 04/29/2014] [Accepted: 04/30/2014] [Indexed: 11/16/2022]
|
30
|
Maksimenko A, Alami M, Zouhiri F, Brion JD, Pruvost A, Mougin J, Hamze A, Boissenot T, Provot O, Desmaële D, Couvreur P. Therapeutic modalities of squalenoyl nanocomposites in colon cancer: an ongoing search for improved efficacy. ACS NANO 2014; 8:2018-32. [PMID: 24555414 PMCID: PMC4060170 DOI: 10.1021/nn500517a] [Citation(s) in RCA: 54] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/05/2013] [Accepted: 02/20/2014] [Indexed: 05/23/2023]
Abstract
Drug delivery of combined cytotoxic and antivascular chemotherapies in multidrug nanoassemblies may represent an attractive way to improve the treatment of experimental cancers. Here we made the proof of concept of this approach on the experimental LS174-T human colon carcinoma xenograft nude mice model. Briefly, we have nanoprecipitated the anticancer compound gemcitabine conjugated with squalene (SQ-gem) together with isocombretastatin A-4 (isoCA-4), a new isomer of the antivascular combretastatin A-4 (CA-4). It was found that these molecules spontaneously self-assembled as stable nanoparticles (SQ-gem/isoCA-4 NAs) of ca. 142 nm in a surfactant-free aqueous solution. Cell culture viability tests and apoptosis assays showed that SQ-gem/isoCA-4 NAs displayed comparable antiproliferative and cytotoxic effects than those of the native gemcitabine or the mixtures of free gemcitabine with isoCA-4. Surprisingly, it was observed by confocal microscopy that the nanocomposites made of SQ-gem/isoCA-4 distributed intracellularly as intact nanoparticles whereas the SQ-gem nanoparticles remained localized onto the cell membrane. When used to deliver these combined chemotherapeutics to human colon cancer model, SQ-gem/isoCA-4 nanocomposites induced complete tumor regression (by 93%) and were found superior to all the other treatments, whereas the overall tolerance was better than the free drug treatments. This approach could be applied to other pairs of squalenoylated nanoassemblies with other non-water-soluble drugs, thus broadening the application of the "squalenoylation" concept in oncology.
Collapse
Affiliation(s)
- Andrei Maksimenko
- Faculté de Pharmacie, Université Paris-Sud, Institut Galien Paris Sud, UMR CNRS 8612, 5 rue J.-B. Clément, Châtenay-Malabry, Paris, F-92296, France
| | - Mouad Alami
- Laboratoire de Chimie Thérapeutique, Equipe Labellisée Ligue Contre le Cancer, LabEx LERMIT, Faculté de Pharmacie, Université Paris-Sud, CNRS, BioCIS-UMR 8076, 5 rue J.-B. Clément, Châtenay-Malabry, Paris, F-92296, France
| | - Fatima Zouhiri
- Faculté de Pharmacie, Université Paris-Sud, Institut Galien Paris Sud, UMR CNRS 8612, 5 rue J.-B. Clément, Châtenay-Malabry, Paris, F-92296, France
| | - Jean-Daniel Brion
- Laboratoire de Chimie Thérapeutique, Equipe Labellisée Ligue Contre le Cancer, LabEx LERMIT, Faculté de Pharmacie, Université Paris-Sud, CNRS, BioCIS-UMR 8076, 5 rue J.-B. Clément, Châtenay-Malabry, Paris, F-92296, France
| | - Alain Pruvost
- Laboratoire d’Etude du Métabolisme des Médicaments, iBiTecS, SPI, CEA, Gif sur Yvette, Paris F-91191, France
| | - Julie Mougin
- Faculté de Pharmacie, Université Paris-Sud, Institut Galien Paris Sud, UMR CNRS 8612, 5 rue J.-B. Clément, Châtenay-Malabry, Paris, F-92296, France
| | - Abdallah Hamze
- Laboratoire de Chimie Thérapeutique, Equipe Labellisée Ligue Contre le Cancer, LabEx LERMIT, Faculté de Pharmacie, Université Paris-Sud, CNRS, BioCIS-UMR 8076, 5 rue J.-B. Clément, Châtenay-Malabry, Paris, F-92296, France
| | - Tanguy Boissenot
- Faculté de Pharmacie, Université Paris-Sud, Institut Galien Paris Sud, UMR CNRS 8612, 5 rue J.-B. Clément, Châtenay-Malabry, Paris, F-92296, France
| | - Olivier Provot
- Laboratoire de Chimie Thérapeutique, Equipe Labellisée Ligue Contre le Cancer, LabEx LERMIT, Faculté de Pharmacie, Université Paris-Sud, CNRS, BioCIS-UMR 8076, 5 rue J.-B. Clément, Châtenay-Malabry, Paris, F-92296, France
| | - Didier Desmaële
- Faculté de Pharmacie, Université Paris-Sud, Institut Galien Paris Sud, UMR CNRS 8612, 5 rue J.-B. Clément, Châtenay-Malabry, Paris, F-92296, France
| | - Patrick Couvreur
- Faculté de Pharmacie, Université Paris-Sud, Institut Galien Paris Sud, UMR CNRS 8612, 5 rue J.-B. Clément, Châtenay-Malabry, Paris, F-92296, France
| |
Collapse
|
31
|
Das M, Jain R, Agrawal AK, Thanki K, Jain S. Macromolecular Bipill of Gemcitabine and Methotrexate Facilitates Tumor-Specific Dual Drug Therapy with Higher Benefit-to-Risk Ratio. Bioconjug Chem 2014; 25:501-9. [DOI: 10.1021/bc400477q] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Affiliation(s)
- Manasmita Das
- Centre
for Pharmaceutical
Nanotechnology, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar (Mohali), Punjab 160062, India
| | - Roopal Jain
- Centre
for Pharmaceutical
Nanotechnology, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar (Mohali), Punjab 160062, India
| | - Ashish Kumar Agrawal
- Centre
for Pharmaceutical
Nanotechnology, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar (Mohali), Punjab 160062, India
| | - Kaushik Thanki
- Centre
for Pharmaceutical
Nanotechnology, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar (Mohali), Punjab 160062, India
| | - Sanyog Jain
- Centre
for Pharmaceutical
Nanotechnology, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar (Mohali), Punjab 160062, India
| |
Collapse
|
32
|
Bui DT, Nicolas J, Maksimenko A, Desmaële D, Couvreur P. Multifunctional squalene-based prodrug nanoparticles for targeted cancer therapy. Chem Commun (Camb) 2014; 50:5336-8. [DOI: 10.1039/c3cc47427e] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
33
|
Jain S, Jain R, Das M, Agrawal AK, Thanki K, Kushwah V. Combinatorial bio-conjugation of gemcitabine and curcumin enables dual drug delivery with synergistic anticancer efficacy and reduced toxicity. RSC Adv 2014. [DOI: 10.1039/c4ra04237a] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Enhanced efficacy and reduced cytotoxicity of novel bio-conjugate of gemcitabine and curcumin.
Collapse
Affiliation(s)
- Sanyog Jain
- Centre for Pharmaceutical Nanotechnology
- Department of Pharmaceutics
- National Institute of Pharmaceutical Education and Research (NIPER)
- Punjab-160062, India
| | - Roopal Jain
- Centre for Pharmaceutical Nanotechnology
- Department of Pharmaceutics
- National Institute of Pharmaceutical Education and Research (NIPER)
- Punjab-160062, India
| | - Manasmita Das
- Centre for Pharmaceutical Nanotechnology
- Department of Pharmaceutics
- National Institute of Pharmaceutical Education and Research (NIPER)
- Punjab-160062, India
| | - Ashish K. Agrawal
- Centre for Pharmaceutical Nanotechnology
- Department of Pharmaceutics
- National Institute of Pharmaceutical Education and Research (NIPER)
- Punjab-160062, India
| | - Kaushik Thanki
- Centre for Pharmaceutical Nanotechnology
- Department of Pharmaceutics
- National Institute of Pharmaceutical Education and Research (NIPER)
- Punjab-160062, India
| | - Varun Kushwah
- Centre for Pharmaceutical Nanotechnology
- Department of Pharmaceutics
- National Institute of Pharmaceutical Education and Research (NIPER)
- Punjab-160062, India
| |
Collapse
|
34
|
Gaudin A, Yemisci M, Eroglu H, Lepêtre-Mouelhi S, Turkoglu OF, Dönmez-Demir B, Caban S, Fevzi Sargon M, Garcia-Argote S, Pieters G, Loreau O, Rousseau B, Tagit O, Hildebrandt N, Le Dantec Y, Mougin J, Valetti S, Chacun H, Nicolas V, Desmaële D, Andrieux K, Capan Y, Dalkara T, Couvreur P. Squalenoyl adenosine nanoparticles provide neuroprotection after stroke and spinal cord injury. NATURE NANOTECHNOLOGY 2014; 9:1054-1062. [PMID: 25420034 PMCID: PMC4351925 DOI: 10.1038/nnano.2014.274] [Citation(s) in RCA: 139] [Impact Index Per Article: 13.9] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/17/2013] [Accepted: 10/21/2014] [Indexed: 05/19/2023]
Abstract
There is an urgent need to develop new therapeutic approaches for the treatment of severe neurological trauma, such as stroke and spinal cord injuries. However, many drugs with potential neuropharmacological activity, such as adenosine, are inefficient upon systemic administration because of their fast metabolization and rapid clearance from the bloodstream. Here, we show that conjugation of adenosine to the lipid squalene and the subsequent formation of nanoassemblies allows prolonged circulation of this nucleoside, providing neuroprotection in mouse stroke and rat spinal cord injury models. The animals receiving systemic administration of squalenoyl adenosine nanoassemblies showed a significant improvement of their neurologic deficit score in the case of cerebral ischaemia, and an early motor recovery of the hindlimbs in the case of spinal cord injury. Moreover, in vitro and in vivo studies demonstrated that the nanoassemblies were able to extend adenosine circulation and its interaction with the neurovascular unit. This Article shows, for the first time, that a hydrophilic and rapidly metabolized molecule such as adenosine may become pharmacologically efficient owing to a single conjugation with the lipid squalene.
Collapse
Affiliation(s)
- Alice Gaudin
- Institut Galien Paris-Sud UMR CNRS 8612, Faculty of Pharmacy, University of Paris-Sud XI, 92296 Châtenay-Malabry, France
| | - Müge Yemisci
- Institute of Neurological Sciences and Psychiatry, Hacettepe University, Ankara 06100, Turkey
| | - Hakan Eroglu
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, Ankara 06100, Turkey
| | - Sinda Lepêtre-Mouelhi
- Institut Galien Paris-Sud UMR CNRS 8612, Faculty of Pharmacy, University of Paris-Sud XI, 92296 Châtenay-Malabry, France
| | - Omer Faruk Turkoglu
- Department of Neurosurgery, Ankara Ataturk Research & Education Hospital, 06800 Bilkent Ankara, Turkey
| | - Buket Dönmez-Demir
- Institute of Neurological Sciences and Psychiatry, Hacettepe University, Ankara 06100, Turkey
| | - Seçil Caban
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, Ankara 06100, Turkey
| | - Mustafa Fevzi Sargon
- Department of Anatomy, Faculty of Medicine, Hacettepe University, Ankara 06100, Turkey
| | | | - Grégory Pieters
- CEA Saclay, iBiTecS-S/SCBM, Labex LERMIT, 91191 Gif-sur-Yvette, France
| | - Olivier Loreau
- CEA Saclay, iBiTecS-S/SCBM, Labex LERMIT, 91191 Gif-sur-Yvette, France
| | - Bernard Rousseau
- CEA Saclay, iBiTecS-S/SCBM, Labex LERMIT, 91191 Gif-sur-Yvette, France
| | - Oya Tagit
- NanoBioPhotonics, Institut d’Electronique Fondamentale, University of Paris-Sud XI, 91405, Orsay Cedex, France
| | - Niko Hildebrandt
- NanoBioPhotonics, Institut d’Electronique Fondamentale, University of Paris-Sud XI, 91405, Orsay Cedex, France
| | - Yannick Le Dantec
- EA3544, Faculty of Pharmacy, University of Paris-Sud XI, 92296 Châtenay-Malabry, France
| | - Julie Mougin
- Institut Galien Paris-Sud UMR CNRS 8612, Faculty of Pharmacy, University of Paris-Sud XI, 92296 Châtenay-Malabry, France
| | - Sabrina Valetti
- Institut Galien Paris-Sud UMR CNRS 8612, Faculty of Pharmacy, University of Paris-Sud XI, 92296 Châtenay-Malabry, France
| | - Hélène Chacun
- Institut Galien Paris-Sud UMR CNRS 8612, Faculty of Pharmacy, University of Paris-Sud XI, 92296 Châtenay-Malabry, France
| | - Valérie Nicolas
- Institut d’Innovation Thérapeutique, IFR141 ITFM, Faculty of Pharmacy, University of Paris-Sud XI, 92296 Châtenay-Malabry, France
| | - Didier Desmaële
- Institut Galien Paris-Sud UMR CNRS 8612, Faculty of Pharmacy, University of Paris-Sud XI, 92296 Châtenay-Malabry, France
| | - Karine Andrieux
- Institut Galien Paris-Sud UMR CNRS 8612, Faculty of Pharmacy, University of Paris-Sud XI, 92296 Châtenay-Malabry, France
- Correspondence and requests for materials should be adressed to P.C. and K.A. ,
| | - Yilmaz Capan
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, Ankara 06100, Turkey
| | - Turgay Dalkara
- Institute of Neurological Sciences and Psychiatry, Hacettepe University, Ankara 06100, Turkey
| | - Patrick Couvreur
- Institut Galien Paris-Sud UMR CNRS 8612, Faculty of Pharmacy, University of Paris-Sud XI, 92296 Châtenay-Malabry, France
- Correspondence and requests for materials should be adressed to P.C. and K.A. ,
| |
Collapse
|
35
|
Lepeltier E, Bourgaux C, Rosilio V, Poupaert JH, Meneau F, Zouhiri F, Lepêtre-Mouelhi S, Desmaële D, Couvreur P. Self-assembly of squalene-based nucleolipids: relating the chemical structure of the bioconjugates to the architecture of the nanoparticles. LANGMUIR : THE ACS JOURNAL OF SURFACES AND COLLOIDS 2013; 29:14795-803. [PMID: 24219056 DOI: 10.1021/la403338y] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
Squalene-based nucleolipids, including anticancer or antiviral prodrugs, gave rise to nanoparticles displaying a diversity of structures upon nanoprecipitation in water. Synchrotron small-angle X-ray scattering and cryo-TEM imaging revealed that both the nature of the nucleoside and the position of the squalene moiety relative to the nucleobase determined the self-assembly of the corresponding bioconjugates. It was found that small chemical differences resulted in major differences in the self-organization of nucleolipids when squalene was grafted onto the nucleobase whereas only lamellar phases were observed when squalene was linked to the sugar moiety. The key role of hydrogen bonds between nucleobases in the formation of the lamellar phases was suggested, in agreement with molecular simulations. These findings provide a way to fine tune the supramolecular organization of squalene-based prodrugs, with the aim of improving their pharmacological activity.
Collapse
Affiliation(s)
- Elise Lepeltier
- Univ. Paris-Sud XI, Faculté de Pharmacie, UMR CNRS 8612-Institut Galien Paris-Sud , 92296 Châtenay-Malabry Cedex, France
| | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Trung Bui D, Maksimenko A, Desmaële D, Harrisson S, Vauthier C, Couvreur P, Nicolas J. Polymer Prodrug Nanoparticles Based on Naturally Occurring Isoprenoid for Anticancer Therapy. Biomacromolecules 2013; 14:2837-47. [DOI: 10.1021/bm400657g] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Affiliation(s)
- Duc Trung Bui
- Institut Galien Paris-Sud, Université Paris-Sud, UMR CNRS 8612, Faculté de Pharmacie,
5 rue Jean-Baptiste Clément, F-92296 Châtenay-Malabry
cedex, France
| | - Andrei Maksimenko
- Institut Galien Paris-Sud, Université Paris-Sud, UMR CNRS 8612, Faculté de Pharmacie,
5 rue Jean-Baptiste Clément, F-92296 Châtenay-Malabry
cedex, France
| | - Didier Desmaële
- Institut Galien Paris-Sud, Université Paris-Sud, UMR CNRS 8612, Faculté de Pharmacie,
5 rue Jean-Baptiste Clément, F-92296 Châtenay-Malabry
cedex, France
| | - Simon Harrisson
- Institut Galien Paris-Sud, Université Paris-Sud, UMR CNRS 8612, Faculté de Pharmacie,
5 rue Jean-Baptiste Clément, F-92296 Châtenay-Malabry
cedex, France
| | - Christine Vauthier
- Institut Galien Paris-Sud, Université Paris-Sud, UMR CNRS 8612, Faculté de Pharmacie,
5 rue Jean-Baptiste Clément, F-92296 Châtenay-Malabry
cedex, France
| | - Patrick Couvreur
- Institut Galien Paris-Sud, Université Paris-Sud, UMR CNRS 8612, Faculté de Pharmacie,
5 rue Jean-Baptiste Clément, F-92296 Châtenay-Malabry
cedex, France
| | - Julien Nicolas
- Institut Galien Paris-Sud, Université Paris-Sud, UMR CNRS 8612, Faculté de Pharmacie,
5 rue Jean-Baptiste Clément, F-92296 Châtenay-Malabry
cedex, France
| |
Collapse
|
37
|
Hillaireau H, Dereuddre-Bosquet N, Skanji R, Bekkara-Aounallah F, Caron J, Lepêtre S, Argote S, Bauduin L, Yousfi R, Rogez-Kreuz C, Desmaële D, Rousseau B, Gref R, Andrieux K, Clayette P, Couvreur P. Anti-HIV efficacy and biodistribution of nucleoside reverse transcriptase inhibitors delivered as squalenoylated prodrug nanoassemblies. Biomaterials 2013; 34:4831-8. [PMID: 23562054 DOI: 10.1016/j.biomaterials.2013.03.022] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2012] [Accepted: 03/09/2013] [Indexed: 02/04/2023]
Abstract
Due to their hydrophilic nature, most nucleoside reverse transcriptase inhibitors (NRTIs) display a variable bioavailability after oral administration and a poor control over their biodistribution, thus hampering their access to HIV sanctuaries. The limited cellular uptake and activation in the triphosphate form of NRTIs further restrict their efficacy and favour the emergence of viral resistance. We have shown that the conjugation of squalene (sq) to the nucleoside analogues dideoxycytidine (ddC) and didanosine (ddI) leads to amphiphilic prodrugs (ddC-sq and ddI-sq) that spontaneously self-organize in water as stable nanoassemblies of 100-300 nm. These nanoassemblies can also be formulated with polyethylene glycol coupled to either cholesterol (Chol-PEG) or squalene (sq-PEG). When incubated with peripheral blood mononuclear cells (PBMCs) in vitro infected with HIV, the NRTI-sq prodrugs enhanced the antiviral efficacy of the parent NRTIs, with a 2- to 3-fold decrease of the 50% effective doses and a nearly 2-fold increase of the selectivity index. This was also the case with HIV-1 strains resistant to ddC and/or ddI. The enhanced antiviral activity of ddI-sq was correlated with an up to 5-fold increase in the intracellular concentration of the corresponding pharmacologically active metabolite ddA-TP. The ddI-sq prodrug was further investigated in vivo by the oral route, the preferred route of administration of NRTIs. Pharmacokinetics studies performed on rats showed that the prodrug maintained low amounts of free ddI in the plasma. Administration of (3)H-ddI-sq led to radioactivity levels higher in the plasma and relevant organs in HIV infection as compared to administration of free (3)H-ddI. Taken together, these results show the potential of the squalenoylated prodrugs of NRTIs to enhance their absorption and improve their biodistribution, but also to enhance their intracellular delivery and antiviral efficacy towards HIV-infected cells.
Collapse
Affiliation(s)
- Hervé Hillaireau
- Institut Galien Paris-Sud, UMR 8612, Université Paris-Sud, Châtenay-Malabry, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Abstract
The use of nanotechnologies for the targeted delivery of therapeutic agents is a research strategy which can lead to more efficacious drugs fulfilling unmet medical needs. The morphology, supramolecular organization and properties of first, second and third generation nanocarriers used for the targeted delivery of drugs are discussed. These different nanocarriers (liposomes, nanoparticles, polymers, etc.) may: (I) protect the drug from degradation by the biological environment; (II) allow the controlled delivery of the active molecule by an external stimulus; (III) avoid the recognition of the drug by the reticulo-endothelial system; (IV) overcome multidrug resistance mechanisms of cancer cells and finally (V) very specifically target the therapeutic agent to the diseased cell by means of selective ligands. Some therapeutic applications of these different types of nanocarriers are discussed, especially in the field of cancer therapy. Finally, the future challenges and perspectives of nanotechnologies, especially for "theragnostic" and gene therapy are briefly discussed.
Collapse
Affiliation(s)
- Patrick Couvreur
- Faculté de Pharmacie, UMR CNRS 8612, Universit´e Paris-Sud 11, 5 rue J.B. Cl´ement, 92296 Chatenay Malabry, France.
| |
Collapse
|
39
|
Shan T, Ma Q, Guo K, Liu J, Li W, Wang F, Wu E. Xanthones from mangosteen extracts as natural chemopreventive agents: potential anticancer drugs. Curr Mol Med 2012; 11:666-77. [PMID: 21902651 DOI: 10.2174/156652411797536679] [Citation(s) in RCA: 135] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2011] [Revised: 06/27/2011] [Accepted: 07/15/2011] [Indexed: 11/22/2022]
Abstract
Despite decades of research, the treatment and management of malignant tumors still remain a formidable challenge for public health. New strategies for cancer treatment are being developed, and one of the most promising treatment strategies involves the application of chemopreventive agents. The search for novel and effective cancer chemopreventive agents has led to the identification of various naturally occurring compounds. Xanthones, from the pericarp, whole fruit, heartwood, and leaf of mangosteen (Garcinia mangostana Linn., GML), are known to possess a wide spectrum of pharmacologic properties, including antioxidant, anti- tumor, anti-allergic, anti-inflammatory, anti-bacterial, anti-fungal, and anti-viral activities. The potential chemopreventive and chemotherapeutic activities of xanthones have been demonstrated in different stages of carcinogenesis (initiation, promotion, and progression) and are known to control cell division and growth, apoptosis, inflammation, and metastasis. Multiple lines of evidence from numerous in vitro and in vivo studies have confirmed that xanthones inhibit proliferation of a wide range of human tumor cell types by modulating various targets and signaling transduction pathways. Here we provide a concise and comprehensive review of preclinical data and assess the observed anticancer effects of xanthones, supporting its remarkable potential as an anticancer agent.
Collapse
Affiliation(s)
- T Shan
- Department of Hepatobiliary Surgery, First Affiliated Hospital of Medical College, Xi’an Jiaotong University, Xi’an 710061, Shaanxi, China
| | | | | | | | | | | | | |
Collapse
|
40
|
Desmaële D, Gref R, Couvreur P. Squalenoylation: A generic platform for nanoparticular drug delivery. J Control Release 2012; 161:609-18. [DOI: 10.1016/j.jconrel.2011.07.038] [Citation(s) in RCA: 106] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2011] [Revised: 07/22/2011] [Accepted: 07/23/2011] [Indexed: 01/02/2023]
|
41
|
Cosco D, Rocco F, Ceruti M, Vono M, Fresta M, Paolino D. Self-assembled squalenoyl-cytarabine nanostructures as a potent nanomedicine for treatment of leukemic diseases. Int J Nanomedicine 2012; 7:2535-46. [PMID: 22679366 PMCID: PMC3367491 DOI: 10.2147/ijn.s28114] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
Background In this investigation, the antileukemic activity of a new nanomedicine based on the conjugation of 1,1′,2-tris-nor-squalenic acid with cytarabine (Ara-C) was evaluated. Methods Squalenoyl-Ara-C conjugate (Sq-Ara-C) self-assembled nanosystems were obtained by the nanoprecipitation method and characterized in vitro and in vivo. Results This new nanomedicine, which had a mean diameter of approximately 150 nm, improved the in vitro antitumoral activity of Ara-C in different cancer cell lines (L1210, K562, and MCF-7). Sq-Ara-C nanomedicine allowed reduction of the IC50 value with respect to the free drug and was also active against drug-resistant leukemic cells (L1210R). A noticeable increase in the survival rate of mice with aggressive metastatic L1210R leukemia was observed after treatment with Sq-Ara-C (50 mg/kg) as compared with the free active compound (100 mg/kg). Finally, evaluation of the biodistribution and pharmacokinetic profiles of the drug demonstrated that these nanoaggregates preferentially localized to the liver and spleen, and protected the drug from physiological metabolism. Conclusion Squalenoylation of cytarabine offers several pharmacological benefits both in vitro and in vivo.
Collapse
Affiliation(s)
- Donato Cosco
- Department of Health Sciences, University Magna Græcia, Catanzaro, Italy
| | | | | | | | | | | |
Collapse
|
42
|
Kim SK, Karadeniz F. Biological importance and applications of squalene and squalane. ADVANCES IN FOOD AND NUTRITION RESEARCH 2012; 65:223-33. [PMID: 22361190 DOI: 10.1016/b978-0-12-416003-3.00014-7] [Citation(s) in RCA: 130] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Abstract
Squalene is a polyunsaturated hydrocarbon with a formula of C₃₀H₅₀. Squalene can be found in certain fish oils, especially shark liver oil, in high amounts and some vegetable oils in relatively smaller amounts. Human sebum also contains 13% squalene as one of its major constituents. Squalane is a saturated derivative of squalene and also found in these sources. Interest in squalene has been raised after its characterization in shark liver oil which is used as a traditional medicine for decades. Several studies exhibited results that prove certain bioactivities for squalene and squalane. Up to date, anticancer, antioxidant, drug carrier, detoxifier, skin hydrating, and emollient activities of these substances have been reported both in animal models and in vitro environments. According to promising results from recent studies, squalene and squalane are considered important substances in practical and clinical uses with a huge potential in nutraceutical and pharmaceutical industries.
Collapse
Affiliation(s)
- Se-Kwon Kim
- Department of Chemistry, Pukyong National University, Busan, Republic of Korea.
| | | |
Collapse
|
43
|
Allain V, Bourgaux C, Couvreur P. Self-assembled nucleolipids: from supramolecular structure to soft nucleic acid and drug delivery devices. Nucleic Acids Res 2011; 40:1891-903. [PMID: 22075995 PMCID: PMC3300006 DOI: 10.1093/nar/gkr681] [Citation(s) in RCA: 85] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
This short review aims at presenting some recent illustrative examples of spontaneous nucleolipids self-assembly. High-resolution structural investigations reveal the diversity and complexity of assemblies formed by these bioinspired amphiphiles, resulting from the interplay between aggregation of the lipid chains and base–base interactions. Nucleolipids supramolecular assemblies are promising soft drug delivery systems, particularly for nucleic acids. Regarding prodrugs, squalenoylation is an innovative concept for improving efficacy and delivery of nucleosidic drugs.
Collapse
Affiliation(s)
- Vanessa Allain
- Laboratoire de Physicochimie, Pharmacotechnie et Biopharmacie, UMR CNRS 8612, Université Paris-Sud 11, Faculté de Pharmacie, 5 rue J.B. Clément, 92296 Châtenay-Malabry, France
| | | | | |
Collapse
|
44
|
Celia C, Cosco D, Paolino D, Fresta M. Gemcitabine-loaded innovative nanocarriers vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity. Expert Opin Drug Deliv 2011; 8:1609-29. [PMID: 22077480 DOI: 10.1517/17425247.2011.632630] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
INTRODUCTION Gemcitabine, an anticancer drug, is a nucleoside analog deoxycytidine antimetabolite, which acts against a wide range of solid tumors. The limitation of gemcitabine is its rapid inactivation by the deoxycytidine deaminase enzyme following its in vivo administration. AREAS COVERED One of the most promising new approaches for improving the biopharmaceutical properties of gemcitabine is the use of innovative drug delivery devices. This review explains the current status of gemcitabine drug delivery, which has been under development over the past 5 years, with particular emphasis on liposomal delivery. In addition, the use of novel supramolecular vesicular aggregates (SVAs), polymeric nanoparticles and squalenoylation were treated as interesting innovative approaches for the administration of the nucleoside analog. EXPERT OPINION Different colloidal systems containing gemcitabine have been realized, with the aim of providing important potential advancements through traditional ways of therapy. A possible future commercialization of modified gemcitabine is desirable, as was true in the case of liposomal doxorubicin (Doxil(®), Caely(®)).
Collapse
Affiliation(s)
- Christian Celia
- The Methodist Hospital Research Institute, Department of Nanomedicine, 6670 Bertner St, Houston, TX 77030, USA
| | | | | | | |
Collapse
|
45
|
Bildstein L, Pili B, Marsaud V, Wack S, Meneau F, Lepêtre-Mouelhi S, Desmaële D, Bourgaux C, Couvreur P, Dubernet C. Interaction of an amphiphilic squalenoyl prodrug of gemcitabine with cellular membranes. Eur J Pharm Biopharm 2011; 79:612-20. [DOI: 10.1016/j.ejpb.2011.07.003] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2010] [Revised: 06/27/2011] [Accepted: 07/08/2011] [Indexed: 01/18/2023]
|
46
|
Shan T, Ma Q, Zhang D, Guo K, Liu H, Wang F, Wu E. β2-adrenoceptor blocker synergizes with gemcitabine to inhibit the proliferation of pancreatic cancer cells via apoptosis induction. Eur J Pharmacol 2011; 665:1-7. [PMID: 21570961 DOI: 10.1016/j.ejphar.2011.04.055] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2010] [Revised: 04/18/2011] [Accepted: 04/20/2011] [Indexed: 01/24/2023]
Abstract
The stimulation of β2-adrenoceptor, which is a major mediator for chronic stress-induced cancers, has been implicated in the progression in the number of cancer cells, including pancreatic cancer, which remains one of the most aggressive and lethal diseases worldwide. Whether β-adrenoceptor antagonists potentiate gemcitabine, a standard first-line treatment for advanced pancreatic cancer that offers only modest benefit due to acquired chemoresistance, has not been elucidated. Thus, we studied the antiproliferative and apoptotic effects and the underlying mechanisms of gemcitabine combined with the β2-adrenoceptor blocker ICI 118551 (1-[2,3-(dihydro-7-methyl-1H-iden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-butanol), in human pancreatic cancer BxPC-3 and MIA PaCa-2 cells. Results show that ICI 118551 significantly synergized the antiproliferative and pro-apoptotic effects induced by gemcitabine in both BxPC-3 and MIA PaCa-2 cells (P<0.05 combination vs. control or gemcitabine alone). When cells were treated with the combination of gemcitabine and ICI 118551, NF-κB activation was blocked; the expression of Bax protein was substantially increased; and Bcl-2 protein was downregulated. Taken together, the data suggest that ICI 118551 potentiates the antiproliferative effects of gemcitabine by inducing apoptosis in pancreatic cancer cells. Our study implies that this combination may be an effective therapeutic strategy for pancreatic cancer.
Collapse
Affiliation(s)
- Tao Shan
- Department of Hepatobiliary Surgery, First Affiliated Hospital of Medical College, Xi'an Jiaotong University, Shaanxi Province, China
| | | | | | | | | | | | | |
Collapse
|
47
|
Ambike A, Rosilio V, Stella B, Lepêtre-Mouelhi S, Couvreur P. Interaction of self-assembled squalenoyl gemcitabine nanoparticles with phospholipid-cholesterol monolayers mimicking a biomembrane. LANGMUIR : THE ACS JOURNAL OF SURFACES AND COLLOIDS 2011; 27:4891-4899. [PMID: 21413743 DOI: 10.1021/la200002d] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Gemcitabine (dFdC or Gem) is a water-soluble cytotoxic drug, with poor cellular uptake in the absence of a nucleoside transporter. To improve its diffusion through membranes, it was modified by grafting of a squalenoyl moiety. In water, this derivative is able to form stable and monodispersed nanoparticles made of inverse hexagonal phases. The formation and interfacial properties of the squalenoyl gemcitabine (SQ-Gem) nanoparticles, and their ability to interact with phospholipid and cholesterol monolayers modeling a biomembrane, was assessed from surface tension measurements and Brewster angle microscopy. To get a better insight into the mechanisms of SQ-Gem interaction with the various lipids, the interfacial behavior of SQ-Gem and squalene was also studied by surface pressure and surface potential measurements, in the absence and in the presence of phospholipids and cholesterol. The results showed that SQ-Gem nanoparticles adsorbed at the free air/water interface and disrupted to form a monolayer. SQ-Gem molecules released from the adsorbed nanoparticles were also able to penetrate into condensed phospholipid-cholesterol mixed monolayers. The kinetics of this penetration was apparently controlled by intermolecular interactions between the drug and the adsorbed lipids. Whereas distearoylphosphatidylcholine (DSPC) hindered SQ-Gem penetration, cholesterol favored it, which could have important implications in the therapeutic field since cholesterol targeting could alter lipid raft composition and cancer cell survival.
Collapse
Affiliation(s)
- Anshuman Ambike
- Université Paris-Sud, CNRS UMR 8612, Faculté de Pharmacie, Châtenay-Malabry, France
| | | | | | | | | |
Collapse
|
48
|
Réjiba S, Reddy LH, Bigand C, Parmentier C, Couvreur P, Hajri A. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2011; 7:841-9. [PMID: 21419876 DOI: 10.1016/j.nano.2011.02.012] [Citation(s) in RCA: 76] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/13/2010] [Revised: 01/21/2011] [Accepted: 02/22/2011] [Indexed: 01/29/2023]
Abstract
UNLABELLED Development of chemoresistance and rapid inactivation of gemcitabine (Gem), the standard therapy for advanced pancreatic cancer, are responsible of the major therapeutic failures. To overcome the above drawbacks we designed a novel nanomedicine strategy for Gem nanoparticle (NP) formulation based on squalene conjugation. The purpose was to investigate the antitumor efficacy of gemcitabine-squalene (SQ-Gem) NPs on chemoresistant and chemosensitive pancreatic adenocarcinoma models. Cell viability and apoptosis assays showed that SQ-Gem NPs displayed higher antiproliferative and cytotoxic effects, particularly in chemoresistant Panc1 tumor cells. In in vivo studies, compared to native Gem, SQ-Gem NPs decreased significantly the tumor growth, prevented tumor cell invasion, and prolonged the survival time of mice bearing orthotopic pancreatic tumors. These results correlate with a greater reduction of Ki-67 and induction of apoptosis. These findings demonstrate the feasibility of utilizing SQ-Gem NPs to make tumor cells more sensitive to Gem and thus provide an efficient new therapeutic alternative for pancreatic adenocarcinoma. FROM THE CLINICAL EDITOR Pancreatic malignancies represent some of the most notoriously treatment resistant cancer varieties. This paper discusses a novel and promising nanotechnology-based treatment approach, currently at the basic science stage.
Collapse
|
49
|
Caron J, Lepeltier E, Reddy LH, Lepêtre-Mouelhi S, Wack S, Bourgaux C, Couvreur P, Desmaële D. Squalenoyl Gemcitabine Monophosphate: Synthesis, Characterisation of Nanoassemblies and Biological Evaluation. European J Org Chem 2011. [DOI: 10.1002/ejoc.201100036] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
50
|
Interaction of a new anticancer prodrug, gemcitabine–squalene, with a model membrane. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES 2010; 1798:1522-32. [DOI: 10.1016/j.bbamem.2010.04.011] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/17/2009] [Revised: 04/07/2010] [Accepted: 04/23/2010] [Indexed: 12/28/2022]
|